This is a list of disorder codes in the Online Mendelian Inheritance in Man (OMIM) database. These are diseases that can be inherited via a Mendelian genetic mechanism. OMIM is one of the databases housed in the U.S. National Center for Biotechnology Information.

Isolated 17,20-lyase deficiency;  202110; CYP17A1
17-alpha-hydroxylase/17,20-lyase deficiency;  202110; CYP17A1
17-beta-hydroxysteroid dehydrogenase X deficiency;  300438; HSD17B10
2-methylbutyrylglycinuria;  610006; ACADSB
3-hydroxyacyl-coa dehydrogenase deficiency;  231530; HADHSC
3-hydroxyisobutryl-CoA hydrolase deficiency;  250620; HIBCH
3-M syndrome;  273750; CUL7
3-Methylcrotonyl-CoA carboxylase 1 deficiency;  210200; MCCC1
3-Methylcrotonyl-CoA carboxylase 2 deficiency;  210210; MCCC2
3-Methylglutaconic aciduria type I;  250950; AUH
3-Methylglutaconic aciduria type III;  258501; OPA3
3-Methylglutaconic aciduria type V;  610198; DNAJC19
46XX true hermaphroditism;  400045; SRY
46XY complete gonadal dysgenesis;  233420; DHH
46XY complete gonadal dysgenesis;  400044; SRY
46XY gonadal dysgenesis, complete or partial, with or without adrenal failure;  612965; NR5A1
46XY gonadal dysgenesis, complete, CBS2-related;  613080; CBX2
46XY partial gonadal dysgenesis, with minifascicular neuropathy;  607080; DHH
5-fluorouracil toxicity;  274270; DPYD
6-mercaptopurine sensitivity;  610460; TPMT
Aarskog–Scott syndrome;  305400; FGD1
ABCD syndrome;  600501; EDNRB
Abetalipoproteinemia;  200100; MTP
ACAD9 deficiency;  611126; ACAD9
Acampomelic campomelic dysplasia;  114290; SOX9
Achalasia-Addisonianism-Alacrimia syndrome;  231550; AAAS
Acheiropody;  200500; LMBR1
Achondrogenesis Ib;  600972; SLC26A2
Achondrogenesis type 1A;  200600; TRIP11
Achondrogenesis-hypochondrogenesis type 2;  200610; COL2A1
Achondroplasia;  100800; FGFR3
Achromatopsia-2;  216900; CNGA3
Achromatopsia-3;  262300; CNGB3
Acrocallosal syndrome;  200990; GLI3
Acrocapitofemoral dysplasia;  607778; IHH
Acrodermatitis enteropathica;  201100; SLC39A4
Acrokeratosis verruciformis;  101900; ATP2A2
Acromesomelic dysplasia, Hunter-Thompson type;  201250; GDF5
Acromesomelic dysplasia, Maroteaux type;  602875; NPR2
Action myoclonus-renal failure syndrome;  254900; SCARB2
Acyl-CoA dehydrogenase, long chain, deficiency of;  201460; ACADL
Acyl-CoA dehydrogenase, medium chain, deficiency of;  201450; ACADM
Acyl-CoA dehydrogenase, short chain, deficiency of;  201470; ACADS
Adenocarcinoma of lung, response to tyrosine kinase inhibitor in;  211980; EGFR
Adenocarcinoma of lung, somatic;  211980; BRAF
Adenocarcinoma of lung, somatic;  211980; ERBB2
Adenocarcinoma of lung, somatic;  211980; PRKN
Adenocarcinoma, ovarian, somatic;  604370; PRKN
Adenomas, multiple colorectal;  608456; MUTYH
Adenomas, salivary gland pleomorphic;  181030; PLAG1
Adenomatous polyposis coli;  175100; APC
Adenosine deaminase deficiency, partial;  102700; ADA
Adenosine triphosphate, elevated, of erythrocytes;  102900; PKLR
Adenylosuccinase deficiency;  103050; ADSL
Adiponectin deficiency;  612556; ADIPOQ
Adrenal cortical carcinoma;  202300; TP53
Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency;  202010; CYP11B1
Adrenal hyperplasia, congenital, due to combined P450C17 and P450C21 deficiency;  201750; POR
Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism;  300200; DAX1
Adrenocorticotropic hormone deficiency;  201400; TBS19
Adrenoleukodystrophy;  300100; ABCD1
Adrenoleukodystrophy, neonatal;  202370; PEX1
Adrenoleukodystrophy, neonatal;  202370; PEX10
Adrenoleukodystrophy, neonatal;  202370; PEX13
Adrenoleukodystrophy, neonatal;  202370; PEX26
Adrenoleukodystrophy, neonatal;  202370; PEX5
Adrenomyeloneuropathy;  300100; ABCD1
Adult i phenotype with congenital cataract;  110800; GCNT2
Adult i phenotype without cataract;  110800; GCNT2
ADULT syndrome;  103285; TP63
Advanced sleep phase syndrome, familial;  604348; PER2
Afibrinogenemia, congenital;  202400; FGA
Afibrinogenemia, congenital;  202400; FGB
Agammaglobulinemia 1;  601495; IGHM
Agammaglobulinemia 2;  613500; IGLL1
Agammaglobulinemia 4;  613502; BLNK
Agammaglobulinemia 5;  613506; LRRC8A
Agammaglobulinemia and isolated hormone deficiency;  307200; BTK
Agammaglobulinemia, type 1, X-linked;  300755; BTK
AGAT deficiency;  612718; GATM
Agenesis of the corpus callosum with peripheral neuropathy;  218000; SLC12A6
Aicardi–Goutières syndrome 1, dominant and recessive;  225750; TREX1
Aicardi–Goutières syndrome 2;  610181; RNASEH2B
Aicardi–Goutières syndrome 3;  610329; RNASEH2C
Aicardi–Goutières syndrome 4;  610333; RNASEH2A
Aicardi–Goutières syndrome 5;  612952; SAMHD1
AICA-ribosiduria due to ATIC deficiency;  608688; ATIC
Alagille syndrome 2;  610205; NOTCH2
Alagille syndrome;  118450; JAG1
Aland Island eye disease;  300600; CACNA1F
Albinism, brown oculocutaneous;  203200; OCA2
Albinism, brown;  203290; TYRP1
Albinism, oculocutaneous, type IA;  203100; TYR
Albinism, oculocutaneous, type IB;  606952; TYR
Albinism, oculocutaneous, type II;  203200; OCA2
Albinism, rufous;  278400; TYRP1
Alcohol sensitivity, acute;  610251; ALDH2
Aldosteronism, glucocorticoid-remediable;  103900; CYP11B1
Alexander disease;  203450; GFAP
Alexander disease;  203450; NDUFV1
Alkaptonuria;  203500; HGD
Allan–Herndon–Dudley syndrome;  300523; SLC16A2
Alopecia universalis;  203655; HR
Alopecia, neurologic defects, and endocrinopathy syndrome;  612079; RBM28
Alpers syndrome;  203700; POLG
Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity;  609889; RAG1
Alpha-2-plasmin inhibitor deficiency;  262850; PLI
Alpha-ketoglutarate dehydrogenase deficiency;  203740; OGDH
Alpha-methylacetoacetic aciduria;  203750; ACAT1
Alpha-thalassemia myelodysplasia syndrome, somatic;  300448; ATRX
Alpha-thalassemia mental retardation syndrome;  301040; ATRX
Alport syndrome;  301050; COL4A5
Alport syndrome, autosomal recessive;  203780; COL4A3
Alport syndrome, autosomal recessive;  203780; COL4A4
Alström syndrome;  203800; ALMS1
Alternating hemiplegia of childhood;  104290; ATP1A2
Alveolar capillary dysplasia with misalignment of pulmonary veins;  265380; FOXF1
Alveolar soft part sarcoma;  606243; ASPSCR1
Alzheimer disease 1, familial;  104300; APP
Alzheimer disease 6;  104300; AD6
Alzheimer disease 8;  104300; AD8
Alzheimer disease, late-onset, susceptibility to;  104300; NOS3
Alzheimer disease, type 3;  607822; PSEN1
Alzheimer disease, type 3, with spastic paraparesis and apraxia;  607822; PSEN1
Alzheimer disease, type 3, with spastic paraparesis and unusual plaques;  607822; PSEN1
Alzheimer disease-10;  104300; AD10
Alzheimer disease-2;  104310; APOE
Alzheimer disease-4;  606889; PSEN2
Alzheimer disease-5;  104300; AD5
Amelogenesis imperfecta, hypomaturation type, IIA3;  613211; WDR72
Amelogenesis imperfecta, hypomaturation-hypoplastic type, with taurodontism;  104510; DLX3
Amelogenesis imperfecta, hypoplastic/hypomaturation type;  301200; AMELX
Amelogenesis imperfecta, type 3;  130900; FAM83H
Amelogenesis imperfecta, type IB;  104500; ENAM
Amelogenesis imperfecta, type IC;  204650; ENAM
Amelogenesis imperfecta, type IIA1;  204700; KLK4
Amelogenesis imperfecta, type IIA2;  612529; MMP20
Aminoacylase 1 deficiency;  609924; ACY1
Amish infantile epilepsy syndrome;  609056; SIAT9
Amyloidosis, 3 or more types;  105200; APOA1
Amyloidosis, Finnish type;  105120; GSN
Amyloidosis, hereditary renal;  105200; FGA
Amyloidosis, hereditary, transthyretin-related;  105210; TTR
Amyloidosis, primary localized cutaneous;  105250; OSMR
Amyloidosis, renal;  105200; LYZ
Amyotrophic lateral sclerosis 10, with or without FTD;  612069; TARDBP
Amyotrophic lateral sclerosis 11;  612577; FIG4
Amyotrophic lateral sclerosis 4, juvenile;  602433; SETX
Amyotrophic lateral sclerosis 6, autosomal recessive;  608030; FUS
Amyotrophic lateral sclerosis 8;  608627; VAPB
Amyotrophic lateral sclerosis 9;  611895; ANG
Amyotrophic lateral sclerosis, due to SOD1 deficiency;  105400; SOD1
Amyotrophic lateral sclerosis, juvenile;  205100; ALS2
Amyotrophy, hereditary neuralgic;  162100; 40430
Amytrophic lateral sclerosis 12;  613435; OPTN
Anauxetic dysplasia;  607095; RMRP
Androgen insensitivity syndrome;  300068; AR
Androgen insensitivity, partial, with or without breast cancer;  312300; AR
Anemia, congenital dyserythropoietic, type I;  224120; CDAN1
Anemia, dyserythropoietic congenital, type II;  224100; SEC23B
Anemia, hemolytic, due to UMPH1 deficiency;  266120; NT5C3
Anemia, hemolytic, Rh-null, regulator type;  268150; RHAG
Anemia, hypochromic microcytic;  206100; NRAMP2
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive;  205950; GLRX5
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive;  205950; SLC25A38
Anemia, sideroblastic, with ataxia;  301310; ABCB7
Anemia, sideroblastic, X-linked;  300751; ALAS2
Angelman syndrome;  105830; MECP2
Angelman syndrome;  105830; UBE3A
Angelman syndrome-like;  105830; CDKL5
Angioedema, hereditary, type III;  610618; F12
Angioedema, hereditary, types I and II;  106100; C1NH
Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps;  611773; COL4A1
Aniridia;  106210; PAX6
Anonychia congenita;  206800; RSPO4
Anterior segment mesenchymal dysgenesis;  107250; FOXE3
Anterior segment mesenchymal dysgenesis;  107250; PITX3
Antithrombin III deficiency;  613118; AT3
Antley–Bixler syndrome;  207410; FGFR2
Antley–Bixler syndrome-like with disordered steroidogenesis;  201750; POR
Anxiety-related personality traits;  607834; SLC6A4
Aortic aneurysm, familial thoracic 4;  132900; MYH11
Aortic aneurysm, familial thoracic 6;  611788; ACTA2
Aortic valve disease;  109730; NOTCH1
Apert syndrome;  101200; FGFR2
Aphakia, congenital primary;  610256; FOXE3
Aplasia of lacrimal and salivary glands;  180920; FGF10
Aplastic anemia;  609135; TERC
Argininemia;  207800; ARG1
Argininosuccinic aciduria;  207900; ASL
Aromatase deficiency;  613546; CYP19A1
Aromatase excess syndrome;  139300; CYP19A1
Aromatic L-amino acid decarboxylase deficiency;  608643; DDC
Arrhythmogenic right ventricular dysplasia 1;  107970; TGFB3
Arrhythmogenic right ventricular dysplasia 2;  600996; RYR2
Arrhythmogenic right ventricular dysplasia 5;  604400; LAMR1
Arrhythmogenic right ventricular dysplasia 8;  607450; DSP
Arrhythmogenic right ventricular dysplasia, familial, 10;  610193; DSG2
Arrhythmogenic right ventricular dysplasia, familial, 11;  610476; DSC2
Arrhythmogenic right ventricular dysplasia, familial, 12;  611528; JUP
Arrhythmogenic right ventricular dysplasia, familial, 5;  604400; TMEM43
Arrhythmogenic right ventricular dysplasia, familial, 9;  609040; PKP2
Arterial calcification, generalized, of infancy;  208000; ENPP1
Arterial tortuosity syndrome;  208050; SLC2A10
Arthrogryposis multiplex congenita, distal type 1;  108120; TPM2
Arthrogryposis multiplex congenita, distal type 2B;  601680; TNNI2
Arthrogryposis, distal, type 2A;  193700; MYH3
Arthrogryposis, distal, type 2B;  601680; MYH3
Arthrogryposis, distal, type 2B;  601680; TPM2
Arthrogryposis, lethal, with anterior horn cell disease;  611890; GLE1
Arthrogryposis, renal dysfunction, and cholestasis 1;  208085; VPS33B
Arthrogryposis, renal dysfunction, and cholestasis 2;  613404; VIPAR
Arthropathy, progressive pseudorheumatoid, of childhood;  208230; WISP3
Arthyrgryposis, distal, type 2B;  601680; TNNT3
Arts syndrome;  301835; PRPS1
Aspartylglucosaminuria;  208400; AGA
Asphyxiating thoracic dystrophy 2;  611263; IFT80
Asphyxiating thoracic dystrophy 3;  613091; DYNC2H1
Asthma and nasal polyps;  208550; TBX21
Ataxia with isolated vitamin E deficiency;  277460; TTPA
Ataxia, cerebellar, Cayman type;  601238; ATCAY
Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia;  208920; APTX
Ataxia–ocular apraxia-2;  606002; SETX
Ataxia–telangiectasia;  208900; ATM
Ataxia–telangiectasia-like disorder;  604391; MRE11A
Atelosteogenesis II;  256050; SLC26A2
Atelosteogenesis, type III;  108721; FLNB
Atelostogenesis, type I;  108720; FLNB
Athabaskan brainstem dysgenesis syndrome;  601536; HOXA1
Atopy;  147050; SPINK5
ATP synthase deficiency, nuclear-encoded;  604273; ATPAF2
Atransferrinemia;  209300; TF
Atrial fibrillation;  608583; GJA5
Atrial fibrillation, familial, 3;  607554; KCNQ1
Atrial fibrillation, familial, 4;  611493; KCNE2
Atrial fibrillation, familial, 6;  612201; NPPA
Atrial fibrillation, familial, 7;  612240; KCNA5
Atrial septal defect 4;  611363; TBX20
Atrial septal defect 5;  612794; ACTC1
Atrial septal defect 6;  613087; TLL1
Atrial septal defect with atrioventricular conduction defects;  108900; NKX2E
Atrial septal defect-2;  607941; GATA4
Atrichia with papular lesions;  209500; HR
Atrioventricular canal defect;  600309; AVSD1
Atrioventricular septal defect;  600309; GJA1
Atrioventricular septal defect, partial, with heterotaxy syndrome;  606217; CRELD1
Auditory neuropathy, autosomal recessive, 1;  601071; OTOF
Autoimmune disease, syndromic multisystem;  613385; ITCH
Autoimmune lymphoproliferative syndrome, type IA;  601859; TNFRSF6
Autoimmune lymphoproliferative syndrome, type II;  603909; CASP10
Autoimmune lymphoproliferative syndrome, type IIB;  607271; CASP8
Autoimmune polyendocrinopathy syndrome, type I, with or without reversible metaphyseal dysplasia;  240300; AIRE
Axenfeld–Rieger syndrome, type 1;  180500; PITX2
Axenfeld–Rieger syndrome, type 3;  602482; FOXC1
Azoospermia due to perturbations of meiosis;  270960; SYCP3
Azoospermia;  415000; USP9Y
Baller–Gerold syndrome;  218600; RECQL4
Bamforth–Lazarus syndrome;  241850; FOXE1
Bannayan–Riley–Ruvalcaba syndrome;  153480; PTEN
Bardet–Biedl syndrome 1;  209900; BBS1
Bardet–Biedl syndrome 10;  209900; BBS10
Bardet–Biedl syndrome 11;  209900; TRIM32
Bardet–Biedl syndrome 12;  209900; BBS12
Bardet–Biedl syndrome 13;  209900; MKS1
Bardet–Biedl syndrome 14;  209900; CEP290
Bardet–Biedl syndrome 15;  209900; C2orf86
Bardet–Biedl syndrome 2;  209900; BBS2
Bardet–Biedl syndrome 3;  209900; ARL6
Bardet–Biedl syndrome 4;  209900; BBS4
Bardet–Biedl syndrome 5;  209900; BBS5
Bardet–Biedl syndrome 6;  209900; MKKS
Bardet–Biedl syndrome 7;  209900; BBS7
Bardet–Biedl syndrome 8;  209900; TTC8
Bardet–Biedl syndrome 9;  209900; PTHB1
Bare lymphocyte syndrome, type I;  604571; TAP1
Bare lymphocyte syndrome, type I;  604571; TAPBP
Bare lymphocyte syndrome, type I, due to TAP2 deficiency;  604571; TAP2
Bare lymphocyte syndrome, type II, complementation group A;  209920; MHC2TA
Bare lymphocyte syndrome, type II, complementation group C;  209920; RFX5
Bare lymphocyte syndrome, type II, complementation group D;  209920; RFXAP
Bare lymphocyte syndrome, type II, complementation group E;  209920; RFX5
Barth syndrome;  302060; TAZ
Bart–Pumphrey syndrome;  149200; GJB2
Bartter syndrome, type 1;  601678; SLC12A1
Bartter syndrome, type 2;  241200; KCNJ1
Bartter syndrome, type 3;  607364; CLCNKB
Bartter syndrome, type 4, digenic;  602522; CLCNKB
Bartter syndrome, type 4a;  602522; BSND
Bartter syndrome, type 4b, digenic;  613090; CLCNKA
Basal cell carcinoma, somatic;  605462; PTCH1
Basal cell carcinoma, somatic;  605462; PTCH2
Basal cell carcinoma, somatic;  605462; RASA1
Basal cell nevus syndrome;  109400; PTCH1
Basal ganglia disease, biotin-responsive;  607483; SLC19A3
Basal laminar drusen;  126700; HF1
BCG and salmonella infection, disseminated;  209950; IL12B
BCG infection, generalized familial;  209950; IFNGR1
Beare–Stevenson cutis gyrata syndrome;  123790; FGFR2
Becker muscular dystrophy;  300376; DMD
Beckwith–Wiedemann syndrome;  130650; CDKN1C
Beckwith–Wiedemann syndrome;  130650; H19
Beckwith–Wiedemann syndrome;  130650; KCNQ10T1
Beckwith–Wiedemann syndrome;  130650; NSD1
Bernard–Soulier syndrome, benign autosomal dominant;  153670; GP1BA
Bernard–Soulier syndrome, type A;  231200; GP1BA
Bernard–Soulier syndrome, type B;  231200; GP1BB
Bernard–Soulier syndrome, type C;  231200; GP9
Best macular dystrophy;  153700; BEST1
Bestrophinopathy;  611809; BEST1
Beta-ureidopropionase deficiency;  613161; UPB1
Bethlem myopathy;  158810; COL6A1
Bethlem myopathy;  158810; COL6A2
Bethlem myopathy;  158810; COL6A3
Bietti crystalline corneoretinal dystrophy;  210370; CYP4V2
Bifid nose with or without anorectal and renal anomalies;  608980; FREM1
Bile acid malabsorption, primary;  613291; SLC10A2
Bile acid synthesis defect, congenital, 2;  235555; AKR1D1
Bile acid synthesis defect, congenital, 4;  214950; AMACR
Biotinidase deficiency;  253260; BTD
Birk–Barel mental retardation dysmorphism syndrome;  612292; KCNK9
Birt–Hogg–Dubé syndrome;  135150; FLCN
Björnstad syndrome;  262000; BCS1L
Bladder cancer;  109800; KRAS
Bladder cancer;  109800; RB1
Bladder cancer, somatic;  109800; FGFR3
Blau syndrome;  186580; NOD2
Bleeding disorder due to P2RY12 defect;  609821; P2RY12
Blepharophimosis, epicanthus inversus, and ptosis, type 1;  110100; FOXL2
Blepharophimosis, epicanthus inversus, and ptosis, type 2;  110100; FOXL2
Blood group--Lutheran inhibitor;  111150; KLF1
Bloom syndrome;  210900; RECQL3
Blue cone monochromacy;  303700; OPN1MW
Blue cone monochromacy;  303700; OPN1LW
Boomerang dysplasia;  112310; FLNB
Börjeson–Forssman–Lehmann syndrome;  301900; PHF6
Bosley–Salih–Alorainy syndrome;  601536; HOXA1
Bothnia retinal dystrophy;  607475; RLBP1
Bowen–Conradi syndrome;  211180; EMG1
Brachiootic syndrome 3;  608389; SIX1
Brachydactyly type A1;  112500; BDA1B
Brachydactyly type A1;  112500; IHH
Brachydactyly type A2;  112600; BMPR1B
Brachydactyly type A2;  112600; GDF5
Brachydactyly type B1;  113000; ROR2
Brachydactyly type B2;  611377; NOG
Brachydactyly type C;  113100; GDF5
Brachydactyly type D;  113200; HOXD13
Brachydactyly type E;  113300; HOXD13
Brachydactyly type E2;  613382; PTHLH
Brachydactyly-syndactyly syndrome;  610713; HOXD13
Brachyolmia type 3;  113500; TRPV4
Bradyopsia;  608415; RGS9
Bradyopsia;  608415; RGS9BP
Brain small vessel disease with Axenfeld-Rieger anomaly;  607595; COL4A1
Brain small vessel disease with hemorrhage;  607595; COL4A1
Branchiooculofacial syndrome;  113620; TFAP2A
Branchiootorenal syndrome 2;  610896; SIX5
Branchiootorenal syndrome with cataract;  113650; EYA1
Branchiootorenal syndrome;  113650; EYA1
Breast cancer;  114480; PPM1D
Breast cancer;  114480; SLC22A1L
Breast cancer;  114480; TP53
Breast cancer, early-onset;  114480; BRIP1
Breast cancer, invasive ductal;  114480; RAD54L
Breast cancer, somatic;  114480; AKT1
Breast cancer, somatic;  114480; KRAS
Breast cancer, somatic;  114480; PIK3CA
Breast cancer, somatic;  114480; RB1CC1
Brittle cornea syndrome;  229200; ZNF469
Brody myopathy;  601003; ATP2A1
Bronchiectasis with or without elevated sweat chloride 1;  211400; SCNN1B
Bronchiectasis with or without elevated sweat chloride 2;  613021; SCNN1A
Bronchiectasis with or without elevated sweat chloride 3;  613071; SCNN1G
Brooke–Spiegler syndrome;  605041; CYLD1
Brown–Vialetto–Van Laere syndrome;  211530; C20orf54
Bruck syndrome 2;  609220; PLOD2
Brugada syndrome 1;  601144; SCN5A
Brugada syndrome 2;  611777; GPD1L
Brugada syndrome 3;  611875; CACNA1C
Brugada syndrome 4;  611876; CACNB2
Brugada syndrome 5;  612838; SCN1B
Brugada syndrome 6;  613119; KCNE3
Brugada syndrome 7;  613120; SCN3B
Brugada syndrome 8;  613123; HCN4
Brunner syndrome;  300615; MAOA
Burkitt's lymphoma;  113970; MYC
Buschke–Ollendorff syndrome;  166700; LEMD3
C syndrome;  211750; CD96
C5 deficiency;  609536; C5
C6 deficiency;  612446; C6
C7 deficiency;  610102; C7
Caffey disease;  114000; COL1A1
Campomelic dysplasia with autosomal sex reversal;  114290; SOX9
Campomelic dysplasia;  114290; SOX9
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome;  208250; PRG4
Camurati–Engelmann disease;  131300; TGFB1
Canavan disease;  271900; ASPA
Candidiasis, familial chronic mucocutaneous, autosomal dominant;  613108; CLEC7A
Candidiasis, familial chronic mucocutaneous, autosomal recessive;  212050; CARD9
Capillary malformation-arteriovenous malformation;  608354; RASA1
Carbamoyl phosphate synthetase I deficiency;  237300; CPS1
Carbohydrate-deficient glycoprotein syndrome, type Ib;  602579; MPI
Carboxypeptidase N deficiency;  212070; CPN1
Carcinoid tumors, intestinal;  114900; SDHD
Cardiac arrhythmia, ankyrin-B-related;  600919; ANK2
Cardiac conduction defect, nonspecific;  612838; SCN1B
Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency;  604377; SCO2
Cardiofaciocutaneous syndrome;  115150; BRAF
Cardiofaciocutaneous syndrome;  115150; KRAS
Cardiofaciocutaneous syndrome;  115150; MAP2K1
Cardiofaciocutaneous syndrome;  115150; MAP2K2
Cardiomyopathy, dilated 1C;  601493; LDB3
Cardiomyopathy, dilated;  115200; MYBPC3
Cardiomyopathy, dilated, 1A;  115200; LMNA
Cardiomyopathy, dilated, 1AA;  612158; ACTN2
Cardiomyopathy, dilated, 1BB;  612877; DSG2
Cardiomyopathy, dilated, 1CC;  613122; NEXN
Cardiomyopathy, dilated, 1D;  601494; TNNT2
Cardiomyopathy, dilated, 1DD;  613172; RBM20
Cardiomyopathy, dilated, 1E;  601154; SCN5A
Cardiomyopathy, dilated, 1EE;  613252; MYH6
Cardiomyopathy, dilated, 1FF;  613286; TNNI3
Cardiomyopathy, dilated, 1G;  604145; TTN
Cardiomyopathy, dilated, 1GG;  613642; SDHA
Cardiomyopathy, dilated, 1I;  604765; DES
Cardiomyopathy, dilated, 1J;  605362; EYA4
Cardiomyopathy, dilated, 1L;  606685; SGCD
Cardiomyopathy, dilated, 1M;  607482; CSRP3
Cardiomyopathy, dilated, 1N;  607487; TCAP
Cardiomyopathy, dilated, 1O;  608569; ABCC9
Cardiomyopathy, dilated, 1P;  609909; PLN
Cardiomyopathy, dilated, 1R;  613424; ACTC1
Cardiomyopathy, dilated, 1S;  613426; MYH7
Cardiomyopathy, dilated, 1W;  611407; VCL
Cardiomyopathy, dilated, 1X;  611615; FKTN
Cardiomyopathy, dilated, 1Y;  611878; TPM1
Cardiomyopathy, dilated, 1Z;  611879; TNNC1
Cardiomyopathy, dilated, 2A;  611880; TNNI3
Cardiomyopathy, dilated, 3A;  300069; TAZ
Cardiomyopathy, dilated, 3B;  302045; DMD
Cardiomyopathy, familial hypertrophic, 1;  192600; MYH7
Cardiomyopathy, familial hypertrophic, 10;  608758; MYL2
Cardiomyopathy, familial hypertrophic, 11;  612098; ACTC1
Cardiomyopathy, familial hypertrophic, 12;  612124; CSRP3
Cardiomyopathy, familial hypertrophic, 13;  613243; TNNC1
Cardiomyopathy, familial hypertrophic, 14;  613251; MYH6
Cardiomyopathy, familial hypertrophic, 15;  613255; VCL
Cardiomyopathy, familial hypertrophic;  192600; CAV3
Cardiomyopathy, familial hypertrophic;  192600; SLC25A4
Cardiomyopathy, familial hypertrophic, 2;  115195; TNNT2
Cardiomyopathy, familial hypertrophic, 3;  115196; TPM1
Cardiomyopathy, familial hypertrophic, 4;  115197; MYBPC3
Cardiomyopathy, familial hypertrophic, 8;  608751; MYL3
Cardiomyopathy, familial restrictive;  115210; TNNI3
Cardiomyopathy, familial restrictive, 3;  612422; TNNT2
Cardiomyopathy, hypertrophic 6, with WPW;  600858; PRKAG2
Cardiomyopathy, hypertrophic, midventricular, digenic;  192600; MYLK2
Carney complex variant;  608837; MYH8
Carney complex, type 1;  160980; PRKAR1A
Carnitine deficiency, systemic primary;  212140; SLC22A5
Carotid intimal medial thickness 1;  609338; PPARG
Carpal tunnel syndrome, familial;  115430; TTR
Carpenter syndrome;  201000; RAB23
Cartilage–hair hypoplasia;  250250; RMRP
Cataract with late-onset corneal dystrophy;  604219; PAX6
Cataract, autosomal dominant, multiple types 1;  611597; BFSP2
Cataract, cerulean, type 2;  601547; CRYBB2
Cataract, congenital nuclear, 2;  609741; CRYBB3
Cataract, congenital nuclear, autosomal recessive 3;  611544; CRYBB1
Cataract, congenital zonular, with sutural opacities;  600881; CRYBA1
Cataract, congenital;  604219; BFSP2
Cataract, congenital, cerulean type, 3;  608983; CRYGD
Cataract, congenital, X-linked;  302200; NHS
Cataract, Coppock-like;  604307; CRYBB2
Cataract, Coppock-like;  604307; CRYGC
Cataract, cortical, juvenile-onset;  611391; BFSP1
Cataract, crystalline aculeiform;  115700; CRYGD
Cataract, juvenile, with microcornea and glucosuria;  612018; SLC16A12
Cataract, juvenile-onset;  604219; BFSP2
Cataract, lamellar 2;  610425; CRYBA4
Cataract, lamellar;  116800; HSF4
Cataract, Marner type;  116800; HSF4
Cataract, nonnuclear polymorphic congenital;  601286; CRYGD
Cataract, polymorphic and lamellar;  604219; MIP
Cataract, posterior polar, 1;  613020; EPHA2
Cataract, posterior polar, 3;  605387; CHMP4B
Cataract, posterior polar, 4;  610623; PITX3
Cataract, posterior polar, 4, syndromic;  610623; PITX3
Cataract, sutural, with punctate and cerulean opacities;  607133; CRYBB2
Cataract, zonular pulverulent-1;  116200; GJA8
Cataract, zonular pulverulent-3;  601885; GJA3
Cataract-microcornea syndrome;  116150; GJA8
CATSHL syndrome;  610474; FGFR3
Caudal duplication anomaly;  607864; AXIN1
Caudal regression syndrome;  600145; VANGL1
Cavernous malformations of CNS and retina;  116860; CCM1
CD59 deficiency;  612300; CD59
CD8 deficiency, familial;  608957; CD8A
Cenani–Lenz syndactyly syndrome;  212780; LRP4
Central core disease;  117000; RYR1
Central hypoventilation syndrome;  209880; GDNF
Central hypoventilation syndrome, congenital;  209880; ASCL1
Central hypoventilation syndrome, congenital;  209880; BDNF
Central hypoventilation syndrome, congenital;  209880; EDN3
Central hypoventilation syndrome, congenital;  209880; PMX2B
Central hypoventilation syndrome, congenital;  209880; RET
Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3;  613227; CA8
Cerebellar ataxia;  604290; CP
Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1;  224050; VLDLR
Cerebral amyloid angiopathy;  105150; CST3
Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants;  605714; APP
Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy;  125310; NOTCH3
Cerebral cavernous malformations 3;  603285; PDCD10
Cerebral cavernous malformations-1;  116860; CCM1
Cerebral cavernous malformations-2;  603284; C7orf22
Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome;  609528; SNAP29
Cerebral palsy, spastic quadriplegic, 3;  612936; AP4M1
Cerebral palsy, spastic quadriplegic;  612900; KANK1
Cerebral palsy, spastic, symmetric, autosomal recessive;  603513; GAD1
Cerebrocostomandibular-like syndrome;  611209; COG1
Cerebrooculofacioskeletal syndrome 1;  214150; ERCC6
Cerebrooculofacioskeletal syndrome 2;  610756; ERCC2
Cerebrooculofacioskeletal syndrome 4;  610758; ERCC1
Cerebrotendinous xanthomatosis;  213700; CYP27A1
Ceroid lipofuscinosis, neuronal 8;  600143; CLN8
Ceroid lipofuscinosis, neuronal, 10;  610127; CTSD
Ceroid lipofuscinosis, neuronal, 7;  610951; MFSD8
Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant;  610003; CLN8
Ceroid lipofuscinosis, neuronal 1, infantile;  256730; PPT1
Ceroid-lipofuscinosis, neuronal 2, classic late infantile;  204500; TPP1
Ceroid lipofuscinosis, neuronal 3, juvenile;  204200; CLN3
Ceroid-lipofuscinosis, neuronal-5, variant late infantile;  256731; CLN5
Ceroid-lipofuscinosis, neuronal-6, variant late infantile;  601780; CLN6
Cervical cancer, somatic;  603956; FGFR3
Chanarin–Dorfman syndrome;  275630; ABHD5
Char syndrome;  169100; TFAP2B
Charcot–Marie–Tooth disease, axonal, type 2F;  606595; HSPB1
Charcot–Marie–Tooth disease, axonal, type 2K;  607831; GDAP1
Charcot–Marie–Tooth disease, axonal, type 2L;  608673; HSPB8
Charcot–Marie–Tooth disease, axonal, type 2M;  606482; DNM2
Charcot–Marie–Tooth disease, axonal, type 2N;  613287; AARS
Charcot–Marie–Tooth disease, axonal, with vocal cord paresis;  607706; GDAP1
Charcot–Marie–Tooth disease, dominant intermediate 3;  607791; MPZ
Charcot–Marie–Tooth disease, dominant intermediate B;  606482; DNM2
Charcot–Marie–Tooth disease, dominant intermediate C;  608323; YARS
Charcot–Marie–Tooth disease, recessive intermediate, A;  608340; GDAP1
Charcot–Marie–Tooth disease, recessive intermediate, B;  613641; KARS
Charcot–Marie–Tooth disease type 1A;  118220; PMP22
Charcot–Marie–Tooth disease type 1B;  118200; MPZ
Charcot–Marie–Tooth disease type 1C;  601098; LITAF
Charcot–Marie–Tooth disease type 1D;  607678; EGR2
Charcot–Marie–Tooth disease type 1E;  118300; PMP22
Charcot–Marie–Tooth disease type 1F;  607734; NEFL
Charcot–Marie–Tooth disease type 2A1;  118210; KIF1B
Charcot–Marie–Tooth disease type 2A2;  609260; MFN2
Charcot–Marie–Tooth disease type 2B;  600882; RAB7
Charcot–Marie–Tooth disease type 2B1;  605588; LMNA
Charcot–Marie–Tooth disease type 2B2;  605589; MED25
Charcot–Marie–Tooth disease type 2D;  601472; GARS
Charcot–Marie–Tooth disease type 2E;  607684; NEFL
Charcot–Marie–Tooth disease type 2I;  607677; MPZ
Charcot–Marie–Tooth disease type 2J;  607736; MPZ
Charcot–Marie–Tooth disease type 4A;  214400; GDAP1
Charcot–Marie–Tooth disease type 4B1;  601382; MTMR2
Charcot–Marie–Tooth disease type 4B2;  604563; SBF2
Charcot–Marie–Tooth disease type 4C;  601596; SH3TC2
Charcot–Marie–Tooth disease type 4D;  601455; NDRG1
Charcot–Marie–Tooth disease type 4F;  145900; PRX
Charcot–Marie–Tooth disease type 4H;  609311; FGD4
Charcot–Marie–Tooth disease type 4J;  611228; FIG4
Charcot–Marie–Tooth disease, X-linked recessive, 5;  311070; PRPS1
Charcot–Marie–Tooth neuropathy, X-linked dominant, 1;  302800; GJB1
CHARGE syndrome;  214800; CHD7
CHARGE syndrome;  214800; SEMA3E
Chédiak–Higashi syndrome;  214500; CHS1
Cherubism;  118400; SH3BP2
Chilblain lupus;  610448; TREX1
CHILD syndrome;  308050; NSDHL
Chloride diarrhea, congenital, Finnish type;  214700; SLC26A3
Cholestasis, benign recurrent intrahepatic, 2;  605479; ABCB11
Cholestasis, benign recurrent intrahepatic;  243300; ATP8B1
Cholestasis, familial intrahepatic, of pregnancy;  147480; ABCB4
Cholestasis, progressive familial intrahepatic 1;  211600; ATP8B1
Cholestasis, progressive familial intrahepatic 2;  601847; ABCB11
Cholestasis, progressive familial intrahepatic 3;  602347; ABCB4
Cholestasis, progressive familial intrahepatic 4;  607765; HSD3B7
Cholesteryl ester storage disease;  278000; LIPA
Chondrocalcinosis 2;  118600; ANKH
Chondrodysplasia punctata, rhizomelic, type 2;  222765; GNPAT
Chondrodysplasia punctata, X-linked dominant;  302960; EBP
Chondrodysplasia punctata, X-linked recessive;  302950; ARSL
Chondrodysplasia, Blomstrand type;  215045; PTHR1
Chondrodysplasia, Grebe type;  200700; GDF5
Chondrosarcoma;  215300; EXT1
Chondrosarcoma, extraskeletal myxoid;  612237; TAF15
Chondrosarcoma, extraskeletal myxoid;  612237; TFG
Chondrosarcoma, extraskeletal myxoid;  612237; CSMF
Chorea, hereditary benign;  118700; NKX2-1
Choreoacanthocytosis;  200150; VPS13A
Choreoathetosis, hypothyroidism, and neonatal respiratory distress;  610978; NKX2-1
Choriodal dystrophy, central areolar 2;  613105; PRPH2
Choroid plexus papilloma;  260500; TP53
Choroideremia;  303100; CHM
Chromosome 22q13.3 deletion syndrome;  606232; SHANK3
Chromosome 5q14.3 deletion syndrome;  613443; MEF2C
Chrondrodysplasia, acromesomelic, with genital anomalies;  609441; BMPR1B
Chronic granulomatous disease due to deficiency of NCF-1;  233700; NCF1
Chronic granulomatous disease due to deficiency of NCF-2;  233710; NCF2
Chronic granulomatous disease, autosomal, due to deficiency of CYBA;  233690; CYBA
Chronic granulomatous disease, X-linked;  306400; CYBB
Chylomicron retention disease;  246700; SAR1B
Ciliary dyskinesia, primary, 1, with or without situs inversus;  244400; DNAI1
Ciliary dyskinesia, primary, 10;  612518; KTU
Ciliary dyskinesia, primary, 11;  612649; RSPH4A
Ciliary dyskinesia, primary, 12;  612650; RSPH9
Ciliary dyskinesia, primary, 13;  613193; LRRC50
Ciliary dyskinesia, primary, 3, with or without situs inversus;  608644; DNAH5
Ciliary dyskinesia, primary, 6;  610852; TXNDC3
Ciliary dyskinesia, primary, 7, with or without situs inversus;  611884; DNAH11
Ciliary dyskinesia, primary, 9, with or without situs inversus;  612444; DNAI2
CINCA syndrome;  607115; NLRP3
Cirrhosis, North American Indian childhood type;  604901; CIRH1A
Citrullinemia;  215700; ASS1
Citrullinemia, adult-onset type II;  603471; SLC25A13
Citrullinemia, type II, neonatal-onset;  605814; SLC25A13
Cleft lip/palate-ectodermal dysplasia syndrome;  225060; HVEC
Cleft palate and mental retardation;  119540; SATB2
Cleft palate with ankyloglossia;  303400; TBX22
Cleft palate, isolated;  119540; UBB
Cleidocranial dysplasia;  119600; RUNX2
C-like syndrome;  605039; CD96
Clopidogrel, impaired responsiveness to;  609535; CYP2C
Clubfoot, congenital;  119800; PITX1
COACH syndrome;  216360; CC2D2A
COACH syndrome;  216360; RPGRIP1L
COACH syndrome;  216360; TMEM67
Cockayne syndrome type A;  216400; ERCC8
Cockayne syndrome type B;  133540; ERCC6
Cocoon syndrome;  613630; CHUK
Coenzyme Q10 deficiency;  607426; APTX
Coenzyme Q10 deficiency;  607426; CABC1
Coenzyme Q10 deficiency;  607426; COQ2
Coenzyme Q10 deficiency;  607426; COQ9
Coenzyme Q10 deficiency;  607426; PDSS1
Coenzyme Q10 deficiency;  607426; PDSS2
Coffin–Lowry syndrome;  303600; RPS6KA3
Cohen syndrome;  216550; COH1
Cold-induced autoinflammatory syndrome, familial;  120100; NLRP3
Cold-induced sweating syndrome 1;  610313; CLCF1
Cold-induced sweating syndrome;  272430; CRLF1
Coloboma of optic nerve;  120430; PAX6
Coloboma, ocular;  120200; PAX6
Coloboma, ocular;  120200; SHH
Colon cancer, somatic;  114500; PTPRJ
Colorblindness, deutan;  303800; OPN1MW
Colorblindness, tritan;  190900; OPN1SW
Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas;  132600; MUTYH
Colorectal cancer;  114500; AXIN2
Colorectal cancer;  114500; BUB1B
Colorectal cancer;  114500; EP300
Colorectal cancer;  114500; NRAS
Colorectal cancer;  114500; PDGFRL
Colorectal cancer;  114500; TP53
Colorectal cancer, hereditary nonpolyposis, type 1;  120435; MSH2
Colorectal cancer, hereditary nonpolyposis, type 2;  609310; MLH1
Colorectal cancer, hereditary nonpolyposis, type I;  613244; EPCAM
Colorectal cancer, somatic;  109800; FGFR3
Colorectal cancer, somatic;  114500; AKT1
Colorectal cancer, somatic;  114500; APC
Colorectal cancer, somatic;  114500; FLCN
Colorectal cancer, somatic;  114500; MLH3
Colorectal cancer, somatic;  114500; PIK3CA
Combined cellular and humoral immune defects with granulomas;  233650; RAG1
Combined cellular and humoral immune defects with granulomas;  233650; RAG2
Combined factor V and VIII deficiency;  227300; LMAN1
Combined hyperlipidemia, familial;  144250; LPL
Combined immunodeficiency, X-linked, moderate;  312863; IL2RG
Combined malonic and methylmalonic aciduria (CMAMMA); 614265; ACSF3
Combined malonic and methylmalonic aciduria (CMAMMA); 248360; MLYCD
Combined oxidative phosphorylation deficiency 1;  609060; GFM1
Combined oxidative phosphorylation deficiency 2;  610498; MRPS16
Combined oxidative phosphorylation deficiency 3;  610505; TSFM
Combined oxidative phosphorylation deficiency 4;  610678; TUFM
Combined oxidative phosphorylation deficiency 5;  611719; MRPS22
Combined oxidative phosphorylation deficiency 6;  300816; AIFM1
Combined SAP deficiency;  611721; PSAP
Complement component 4, partial deficiency of;  120790; C1NH
Complement factor H deficiency;  609814; HF1
Complement factor I deficiency;  610984; CFI
Complex I, mitochondrial respiratory chain, deficiency of;  252010; NDUFS6
Cone dystrophy 4;  613093; PDE6C
Cone dystrophy-3;  602093; GUCA1A
Cone–rod dystrophy 10;  610283; SEMA4A
Cone–rod dystrophy 11;  610381; RAXL1
Cone–rod dystrophy 12;  612657; PROM1
Cone–rod dystrophy 13;  608194; RPGRIP1
Cone–rod dystrophy 14;  602093; GUCA1A
Cone–rod dystrophy 15;  613660; CDHR1
Cone–rod dystrophy 3;  604116; ABCA4
Cone–rod dystrophy 5;  600977; PITPNM3
Cone–rod dystrophy;  601777; GUCY2D
Cone–rod dystrophy 7;  603649; RIMS1
Cone–rod dystrophy 9;  612775; ADAM9
Cone–rod dystrophy, X-linked, 3;  300476; CACNA1F
Cone–rod dystrophy-1;  304020; RPGR
Cone–rod retinal dystrophy-2;  120970; CRX
Congenital bilateral absence of vas deferens;  277180; CFTR
Congenital cataracts, facial dysmorphism, and neuropathy;  604168; CTDP1
Congenital disorder of glycosylation, type Ia;  212065; PMM2
Congenital disorder of glycosylation, type Ic;  603147; ALG6
Congenital disorder of glycosylation, type Id;  601110; ALG3
Congenital disorder of glycosylation, type Ie;  608799; DPM1
Congenital disorder of glycosylation, type If;  609180; MPDU1
Congenital disorder of glycosylation, type Ig;  607143; ALG12
Congenital disorder of glycosylation, type Ih;  608104; ALG8
Congenital disorder of glycosylation, type Ii;  607906; ALG2
Congenital disorder of glycosylation, type IIA;  212066; MGAT2
Congenital disorder of glycosylation, type IIb;  606056; GCS1
Congenital disorder of glycosylation type IIc;  266265; SLC35C1
Congenital disorder of glycosylation, type IId;  607091; B4GALT1
Congenital disorder of glycosylation, type IIe;  608779; COG7
Congenital disorder of glycosylation, type IIf;  603585; SLC35A1
Congenital disorder of glycosylation, type IIg;  611209; COG1
Congenital disorder of glycosylation, type IIh;  611182; COG8
Congenital disorder of glycosylation, type IIj;  613489; COG4
Congenital disorder of glycosylation, type Ij;  608093; DPAGT2
Congenital disorder of glycosylation, type Ik;  608540; ALG1
Congenital disorder of glycosylation, type Il;  608776; ALG9
Congenital disorder of glycosylation, type Im;  610768; TMEM15
Congenital disorder of glycosylation, type In;  612015; RFT1
Congenital disorder of glycosylation, type Io;  612937; DPM3
Congenital disorder of glycosylation, type Ip;  612379; SRD5A3
Congenital heart defects, nonsyndromic, 1, X-linked;  306955; ZIC3
Congenital heart disease, nonsyndromic, 2;  612863; TAB2
Conjunctivitis, ligneous;  217090; PLG
Conotruncal anomaly face syndrome;  217095; TBX1
Contractural arachnodactyly, congenital;  121050; FBN2
Convulsions, benign familial infantile, 3;  607745; SCN2A1
Convulsions, familial febrile, 4;  604352; GPR98
COPD, rate of decline of lung function in;  606963; MMP1
Coproporphyria;  121300; CPOX
Cornea plana congenita, recessive;  217300; KERA
Corneal dystrophy polymorphous posterior, 2;  609140; COL8A2
Corneal dystrophy, Avellino type;  607541; TGFBI
Corneal dystrophy, congenital stromal;  610048; DCN
Corneal dystrophy, crystalline, of Schnyder;  121800; UBIAD1
Corneal dystrophy, epithelial basement membrane;  121820; TGFBI
Corneal dystrophy, Fuchs endothelial, 1;  136800; COL8A2
Corneal dystrophy, Fuchs endothelial, 4;  613268; SLC4A11
Corneal dystrophy, Fuchs endothelial, 6;  613270; ZEB1
Corneal dystrophy, gelatinous drop-like;  204870; TACSTD2
Corneal dystrophy, Groenouw type I;  121900; TGFBI
Corneal dystrophy, hereditary polymorphous posterior;  122000; VSX1
Corneal dystrophy, lattice type I;  122200; TGFBI
Corneal dystrophy, lattice type IIIA;  608471; TGFBI
Corneal dystrophy, posterior polymorphous, 3;  609141; ZEB1
Corneal dystrophy, Reis-Bucklers type;  608470; TGFBI
Corneal dystrophy, Thiel-Behnke type;  602082; TGFBI
Corneal endothelial dystrophy 2;  217700; SLC4A11
Corneal endothelial dystrophy and perceptive deafness;  217400; SLC4A11
Corneal fleck dystrophy;  121850; PIKFYVE
Cornelia de Lange syndrome 1;  122470; NIPBL
Cornelia de Lange syndrome 2;  300590; DXS423E
Cornelia de Lange syndrome 3;  610759; CSPG6
Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia;  300472; IGBP1
Corpus callosum, partial agenesis of;  304100; L1CAM
Cortical dysplasia-focal epilepsy syndrome;  610042; CNTNAP2
Corticosteroid-binding globulin deficiency;  611489; CBG
Cortisone reductase deficiency;  604931; H6PD
Cortisone reductase deficiency;  604931; HSD11B1
Costello syndrome;  218040; HRAS
Coumarin resistance;  122700; CYP2A6
Cousin syndrome;  260660; TBX15
Cowden syndrome;  158350; PTEN
Cowden-like syndrome;  612359; SDHB
Cowden-like syndrome;  612359; SDHD
CPT deficiency, hepatic, type IA;  255120; CPT1A
CPT deficiency, hepatic, type II;  600649; CPT2
CPT II deficiency, lethal neonatal;  608836; CPT2
Cranioectodermal dysplasia;  218330; IFT122
Craniofacial-deafness-hand syndrome;  122880; PAX3
Craniofrontonasal dysplasia;  304110; EFNB1
Cranio-lenticulo-sutural dysplasia;  607812; SEC23A
Craniometaphyseal dysplasia;  123000; ANKH
Cranioosteoarthropathy;  259100; HPGD
Craniosynostosis, type 1;  123100; TWIST1
Craniosynostosis, type 2;  604757; MSX2
CRASH syndrome;  303350; L1CAM
Creatine deficiency syndrome, X-linked;  300352; SLC6A8
Creatine phosphokinase, elevated serum;  123320; CAV3
Creutzfeldt–Jakob disease;  123400; PRNP
Crigler–Najjar syndrome type I;  218800; UGT1A1
Crigler–Najjar syndrome type II;  606785; UGT1A1
Crisponi syndrome;  601378; CRLF1
Crouzon syndrome with acanthosis nigricans;  612247; FGFR3
Crouzon syndrome;  123500; FGFR2
Cryptorchidism, bilateral;  219050; LGR8
Cryptorchidism, idiopathic;  219050; INSL3
Currarino syndrome;  176450; MNX1
Cutis laxa with severe pulmonary, gastrointestinal, and urinary abnormalities;  613177; LTBP4
Cutis laxa, AD;  123700; ELN
Cutis laxa, autosomal dominant;  123700; FBLN5
Cutis laxa, autosomal recessive;  219100; FBLN5
Cutis laxa, autosomal recessive, type I;  219100; EFEMP2
Cutis laxa, autosomal recessive, type II;  219200; ATP6V0A2
Cutis laxa, autosomal recessive, type IIB;  612940; PYCR1
Cutis laxa, recessive, type I;  219100; LOX
Cylindromatosis, familial;  132700; CYLD1
Cystathioninuria;  219500; CTH
Cystic fibrosis;  219700; CFTR
Cystinosis, late-onset juvenile or adolescent nephropathic;  219900; CTNS
Cystinosis, nephropathic;  219800; CTNS
Cystinosis, ocular nonnephropathic;  219750; CTNS
Cystinuria;  220100; SLC3A1
Cystinuria;  220100; SLC7A9
Cytochrome C oxidase deficiency;  220110; COX6B1
D-2-hydroxyglutaric aciduria;  600721; D2HGDH
Dandy–Walker malformation;  220200; ZIC1
Dandy–Walker malformation;  220200; ZIC4
Darier disease;  124200; ATP2A2
Darsun syndrome;  612541; G6PC3
D-bifunctional protein deficiency;  261515; HSD17B4
De la Chapelle dysplasia;  256050; SLC26A2
De Sanctis–Cacchione syndrome;  278800; ERCC6
Deafness, autosomal dominant 1;  124900; DIAPH1
Deafness, autosomal dominant 10;  601316; EYA4
Deafness, autosomal dominant 11, neurosensory;  601317; MYO7A
Deafness, autosomal dominant 13;  601868; COL11A2
Deafness, autosomal dominant 15;  602459; POU4F3
Deafness, autosomal dominant 17;  603622; MYH9
Deafness, autosomal dominant 20/26;  604717; ACTG1
Deafness, autosomal dominant 22;  606346; MYO6
Deafness, autosomal dominant 23;  605192; SIX1
Deafness, autosomal dominant 25;  605583; SLC17A8
Deafness, autosomal dominant 28;  608641; GRHL2
Deafness, autosomal dominant 2A;  600101; KCNQ4
Deafness, autosomal dominant 2B;  612644; GJB3
Deafness, autosomal dominant 36;  606705; TMC1
Deafness, autosomal dominant 36, with dentinogenesis;  605594; DSPP
Deafness, autosomal dominant 3A;  601544; GJB2
Deafness, autosomal dominant 3B;  612643; GJB6
Deafness, autosomal dominant 4;  600652; MYH14
Deafness, autosomal dominant 44;  607453; CCDC50
Deafness, autosomal dominant 48;  607841; MYO1A
Deafness, autosomal dominant 5;  600994; DFNA5
Deafness, autosomal dominant 50;  613074; MIR96
Deafness, autosomal dominant 8/12;  601543; TECTA
Deafness, autosomal dominant 9;  601369; COCH
Deafness, autosomal recessive 10, congenital;  605316; TMPRSS3
Deafness, autosomal recessive 12;  601386; CDH23
Deafness, autosomal recessive 16;  603720; STRC
Deafness, autosomal recessive 18;  602092; USH1C
Deafness, autosomal recessive 1A;  220290; GJB2
Deafness, autosomal recessive 1B;  612645; GJB6
Deafness, autosomal recessive 2, neurosensory;  600060; MYO7A
Deafness, autosomal recessive 21;  603629; TECTA
Deafness, autosomal recessive 22;  607039; OTOA
Deafness, autosomal recessive 23;  609533; PCDH15
Deafness, autosomal recessive 25;  613285; GRXCR1
Deafness, autosomal recessive 28;  609823; TRIOBP
Deafness, autosomal recessive 3;  600316; MYO15A
Deafness, autosomal recessive 30;  607101; MYO3A
Deafness, autosomal recessive 31;  607084; WHRN
Deafness, autosomal recessive 35;  608565; ESRRB
Deafness, autosomal recessive 36;  609006; ESPN
Deafness, autosomal recessive 37;  607821; MYO6
Deafness, autosomal recessive 39;  608265; HGF
Deafness, autosomal recessive 49;  610153; MARVELD2
Deafness, autosomal recessive 53;  609706; COL11A2
Deafness, autosomal recessive 59;  610220; PJVK
Deafness, autosomal recessive 6;  600971; TMIE
Deafness, autosomal recessive 63;  611451; LRTOMT
Deafness, autosomal recessive 67;  610265; LHFPL5
Deafness, autosomal recessive 7;  600974; TMC1
Deafness, autosomal recessive 77;  613079; LOXHD1
Deafness, autosomal recessive 79;  613307; TPRN
Deafness, autosomal recessive 8, childhood onset;  601072; TMPRSS3
Deafness, autosomal recessive 84;  613391; PTPRQ
Deafness, autosomal recessive 9;  601071; OTOF
Deafness, autosomal recessive 91;  613453; SERPINB6
Deafness, autosomal recessive, 24;  611022; RDX
Deafness, congenital with inner ear agenesis, microtia, and microdontia;  610706; FGF3
Deafness, digenic GJB2/GJB6;  220290; GJB6
Deafness, digenic, GJB2/GJB3;  220290; GJB3
Deafness, sensorineural, with hypertrophic cardiomyopathy;  606346; MYO6
Deafness, X-linked 1;  304500; PRPS1
Deafness, X-linked 2;  304400; POU3F4
Dehydrated hereditary stomatocytosis, pseudohyperkalemia, and perinatal edema;  603528; PIEZO1
Dejerine–Sottas disease;  145900; PMP22
Dejerine–Sottas neuropathy;  145900; EGR2
Dejerine–Sottas neuropathy, autosomal recessive;  145900; PRX
Dejerine–Sottas syndrome;  145900; MPZ
Dementia, familial British;  176500; ITM2B
Dementia, familial Danish;  117300; ITM2B
Dementia, familial, nonspecific;  600795; CHMP2B
Dementia, frontotemporal;  600274; PSEN1
Dementia, frontotemporal, with or without parkinsonism;  600274; MAPT
Dementia, Lewy body;  127750; SNCA
Dementia, Lewy body;  127750; SNCB
Dent's disease 2;  300555; OCRL
Dent's disease;  300009; CLCN5
Dentatorubr–pallidoluysian atrophy;  125370; ATN1
Dentin dysplasia, type II;  125420; DSPP
Dentinogenesis imperfecta, Shields type II;  125490; DSPP
Dentinogenesis imperfecta, Shields type III;  125500; DSPP
Denys–Drash syndrome;  194080; WT1
Dermatopathia pigmentosa reticularis;  125595; KRT14
Desbuquois dysplasia;  251450; CANT1
Desmoid disease, hereditary;  135290; APC
Desmosterolosis;  602398; DHCR24
Diabetes insipidus, nephrogenic;  125800; AQP2
Diabetes insipidus, nephrogenic;  304800; AVPR2
Diabetes insipidus, neurohypophyseal;  125700; AVP
Diabetes mellitus, gestational;  125851; GCK
Diabetes mellitus, insulin-dependent, 2;  125852; INS
Diabetes mellitus, insulin-dependent, 20;  612520; HNF1A
Diabetes mellitus, insulin-resistant, with acanthosis nigricans;  610549; INSR
Diabetes mellitus, ketosis-prone;  612227; PAX4
Diabetes mellitus, neonatal, with congenital hypothyroidism;  610199; GLIS3
Diabetes mellitus, noninsulin-dependent;  125853; ABCC8
Diabetes mellitus, noninsulin-dependent;  125853; HNF1B
Diabetes mellitus, noninsulin-dependent, late onset;  125853; GCK
Diabetes mellitus, permanent neonatal;  606176; ABCC8
Diabetes mellitus, permanent neonatal;  606176; GCK
Diabetes mellitus, permanent neonatal;  606176; INS
Diabetes mellitus, permanent neonatal, with cerebellar agenesis;  609069; PTF1A
Diabetes mellitus, permanent neonatal, with neurologic features;  606176; KCNJ11
Diabetes mellitus, transient neonatal 2;  610374; ABCC8
Diabetes mellitus, transient neonatal, 1;  601410; ZFP57
Diabetes mellitus, transient neonatal, 3;  610582; KCNJ11
Diabetes mellitus, type 1;  125852; INS
Diabetes mellitus, type 2;  125853; PAX4
Diabetes mellitus type II;  125853; AKT2
Diabetes, permanent neonatal;  606176; KCNJ11
Diamond–Blackfan anemia 1;  105650; RPS19
Diamond–Blackfan anemia 10;  613309; RPS26
Diamond-Blackfan anemia 4;  612527; RPS17
Diamond–Blackfan anemia 5;  612528; RPL35A
Diamond–Blackfan anemia 6;  612561; RPL5
Diamond–Blackfan anemia 7;  612562; RPL11
Diamond–Blackfan anemia 8;  612563; RPS7
Diamond–Blackfan anemia 9;  613308; RPS10
Diamond–Blackfan anemia;  610629; RPS24
Diaphragmatic hernia 3;  610187; ZFPM2
Diarrhea 3, secretory sodium, congenital, syndromic;  270420; SPINT2
Diarrhea 4, malabsorptive, congenital;  610370; NEUROG3
Diarrhea 5, with tufting enteropathy, congenital;  613217; EPCAM
Diastrophic dysplasia;  222600; SLC26A2
Diastrophic dysplasia, broad bone-platyspondylic variant;  222600; SLC26A2
Dicarboxylic aminoaciduria;  222730; SLC1A1
DiGeorge syndrome;  188400; TBX1
Digital clubbing, isolated congenital;  119900; HPGD
Dihydropyrimidine dehydrogenase deficiency;  274270; DPYD
Dihydropyrimidinuria;  222748; DPYS
Dilated cardiomyopathy with woolly hair and keratoderma;  605676; DSP
Dimethylglycine dehydrogenase deficiency;  605850; DMGDH
Disordered steroidogenesis, isolated;  201750; POR
Donnai–Barrow syndrome;  222448; LRP2
Dopamine beta-hydroxylase deficiency;  223360; DBH
Dosage-sensitive sex reversal;  300018; DAX1
Double outlet right ventricle;  217095; CFC1
Double outlet right ventricle;  217095; GDF1
Dowling–Degos disease;  179850; KRT5
Doyne honeycomb degeneration of retina;  126600; EFEMP1
Dravet syndrome;  607208; SCN1A
Duane retraction syndrome 2;  604356; CHN1
Duane-radial ray syndrome;  607323; SALL4
Dubin–Johnson syndrome;  237500; ABCC2
Duchenne muscular dystrophy;  310200; DMD
Dyggve–Melchior–Clausen disease;  223800; DYM
Dysautonomia, familial;  223900; IKBKAP
Dyschromatosis symmetrica hereditaria;  127400; ADAR
Dyserythropoietic anemia with thrombocytopenia;  300367; GATA1
Dyskeratosis congenita;  127550; TERT
Dyskeratosis congenita;  224230; NOLA2
Dyskeratosis congenita, autosomal dominant;  127550; TERC
Dyskeratosis congenita, autosomal dominant;  127550; TINF2
Dyskeratosis congenita, autosomal recessive;  224230; NOLA3
Dyskeratosis congenita-1;  305000; DKC1
Dyssegmental dysplasia, Silverman-Handmaker type;  224410; HSPG2
Dystonia 16;  612067; PRKRA
Dystonia 6, torsion;  602629; THAP1
Dystonia, dopa-responsive, due to sepiapterin reductase deficiency;  612716; SPR
Dystonia, DOPA-responsive, with or without hyperphenylalainemia;  233910; GCH1
Dystonia, juvenile-onset;  607371; ACTB
Dystonia, myoclonic;  159900; DRD2
Dystonia-1, torsion;  128100; DYT1
Dystonia-11, myoclonic;  159900; SGCE
Dystonia-12;  128235; ATP1A3
Dystonia-parkinsonism, adult-onset;  612953; PLA2G6
Dystonia-Parkinsonism, X-linked;  314250; TAF1
EBD inversa;  226600; COL7A1
EBD, Bart type;  132000; COL7A1
Ectodermal dysplasia, anhidrotic, autosomal dominant;  129490; EDARADD
Ectodermal dysplasia, anhidrotic, autosomal recessive;  224900; EDARADD
Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency;  612132; NFKBIA
Ectodermal dysplasia, anhidrotic, X-linked;  305100; ED1
Ectodermal dysplasia, ectrodactyly, and macular dystrophy;  225280; CDH3
Ectodermal dysplasia, hidrotic;  129500; GJB6
Ectodermal dysplasia, hypohidrotic, autosomal dominant;  129490; EDAR
Ectodermal dysplasia, hypohidrotic, autosomal recessive;  224900; EDAR
Ectodermal dysplasia, hypohidrotic, with immune deficiency;  300291; IKBKG
Ectodermal dysplasia, 'pure' hair-nail type;  602032; KRT85
Ectodermal dysplasia-skin fragility syndrome;  604536; PKP1
Ectodermal dysplasia-syndactyly syndrome 1;  613573; PVRL4
Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency;  300301; IKBKG
Ectopia lentis, familial;  129600; FBN1
Ectopia lentis, isolated, autosomal recessive;  225100; ADAMTSL4
Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3;  604292; TP63
Ehlers–Danlos due to tenascin X deficiency;  606408; TNXB
Ehlers–Danlos syndrome, cardiac valvular form;  225320; COL1A2
Ehlers–Danlos syndrome, hypermobility type;  130020; TNXB
Ehlers-Danlos syndrome, musculocontractural type;  601776; CHST14
Ehlers–Danlos syndrome, progeroid form;  130070; B4GALT7
Ehlers–Danlos syndrome, type I;  130000; COL1A1
Ehlers–Danlos syndrome, type I;  130000; COL5A1
Ehlers–Danlos syndrome, type I;  130000; COL5A2
Ehlers–Danlos syndrome, type II;  130010; COL5A1
Ehlers–Danlos syndrome, type III;  130020; COL3A1
Ehlers–Danlos syndrome, type IV;  130050; COL3A1
Ehlers–Danlos syndrome, type VI;  225400; PLOD
Ehlers–Danlos syndrome, type VIIA;  130060; COL1A1
Ehlers–Danlos syndrome, type VIIB;  130060; COL1A2
Ehlers–Danlos syndrome, type VIIC;  225410; ADAMTS2
Eiken syndrome;  600002; PTHR1
Elliptocytosis-1;  611804; EPB41
Elliptocytosis-2;  130600; SPTA1
Ellis–van Creveld syndrome;  225500; EVC
Ellis–van Creveld syndrome;  225500; LBN
Emery–Dreifuss muscular dystrophy 4;  612998; SYNE1
Emery–Dreifuss muscular dystrophy 5;  612999; SYNE2
Emery–Dreifuss muscular dystrophy 6;  300696; FHL1
Emery–Dreifuss muscular dystrophy;  310300; EMD
Emery–Dreifuss muscular dystrophy, AD;  181350; LMNA
Emery–Dreifuss muscular dystrophy, AR;  181350; LMNA
Emphysema due to AAT deficiency;  613490; SERPINA1
Emphysema-cirrhosis, due to AAT deficiency;  613490; SERPINA1
Encephalocardiomyopathy, neonatal, mitochondrial, due to ATP synthase deficiency;  604273; TMEM70
Encephalopathy, familial, with neuroserpin inclusion bodies;  604218; SERPINI1
Encephalopathy, neonatal severe;  300673; MECP2
Endocrine-cerebroosteodysplasia;  612651; ICK
Endometrial cancer;  608089; MLH3
Endometrial cancer, familial;  608089; MSH6
Endplate acetylcholinesterase deficiency;  603034; COLQ
Enhanced S-cone syndrome;  268100; NR2E3
Enlarged vestibular aqueduct;  600791; FOXI1
Enlarged vestibular aqueduct;  600791; SLC26A4
Enterokinase deficiency;  226200; PRSS7
Eosinophil peroxidase deficiency;  261500; EPX
Epidermodysplasia verruciformis;  226400; TMC6
Epidermodysplasia verruciformis;  226400; TMC8
Epidermolysis bullosa dystrophica, AD;  131750; COL7A1
Epidermolysis bullosa dystrophica, AR;  226600; COL7A1
Epidermolysis bullosa of hands and feet;  131800; ITGB4
Epidermolysis bullosa pruriginosa;  604129; COL7A1
Epidermolysis bullosa simplex with migratory circinate erythema;  609352; KRT5
Epidermolysis bullosa simplex with mottled pigmentation;  131960; KRT5
Epidermolysis bullosa simplex with pyloric atresia;  612138; PLEC1
Epidermolysis bullosa simplex, Dowling-Meara type;  131760; KRT14
Epidermolysis bullosa simplex, Dowling-Meara type;  131760; KRT5
Epidermolysis bullosa simplex, Koebner type;  131900; KRT14
Epidermolysis bullosa simplex, Koebner type;  131900; KRT5
Epidermolysis bullosa simplex, Ogna type;  131950; PLEC1
Epidermolysis bullosa simplex, recessive;  601001; KRT14
Epidermolysis bullosa simplex, Weber-Cockayne type;  131800; KRT14
Epidermolysis bullosa simplex, Weber-Cockayne type;  131800; KRT5
Epidermolysis bullosa, generalized atrophic benign;  226650; LAMA3
Epidermolysis bullosa, junctional, Herlitz type;  226700; LAMA3
Epidermolysis bullosa, junctional, Herlitz type;  226700; LAMB3
Epidermolysis bullosa, junctional, Herlitz type;  226700; LAMC2
Epidermolysis bullosa, junctional, non-Herlitz type;  226650; COL17A1
Epidermolysis bullosa, junctional, non-Herlitz type;  226650; ITGB4
Epidermolysis bullosa, junctional, non-Herlitz type;  226650; LAMB3
Epidermolysis bullosa, junctional, non-Herlitz type;  226650; LAMC2
Epidermolysis bullosa, junctional, with pyloric atresia;  226730; ITGB4
Epidermolysis bullosa, junctional, with pyloric stenosis;  226730; ITGA6
Epidermolysis bullosa, lethal acantholytic;  609638; DSP
Epidermolysis bullosa, pretibial;  131850; COL7A1
Epidermolytic hyperkeratosis;  113800; KRT1
Epidermolytic hyperkeratosis;  113800; KRT10
Epidermolytic palmoplantar keratoderma;  144200; KRT9
Epilepsy, benign neonatal, type 2;  121201; KCNQ3
Epilepsy, benign, neonatal, type 1;  121200; KCNQ2
Epilepsy, female-restricted, with mental retardation;  300088; PCDH19
Epilepsy, generalized, with febrile seizures plus, type 2;  604233; SCN1A
Epilepsy, generalized, with febrile seizures plus, type 3;  604233; GABRG2
Epilepsy, juvenile myoclonic, susceptibility to;  613060; GABRD
Epilepsy, myoclonic, Lafora type;  254780; EPM2A
Epilepsy, myoclonic, Lafora type;  254780; NHLRC1
Epilepsy, myoclonic, with mental retardation and spasticity;  300432; ARX
Epilepsy, neonatal myoclonic, with suppression-burst pattern;  609304; SLC25A22
Epilepsy, nocturnal frontal lobe, 1;  600513; CHRNA4
Epilepsy, nocturnal frontal lobe, 3;  605375; CHRNB2
Epilepsy, nocturnal frontal lobe, type 4;  610353; CHRNA2
Epilepsy, partial, with auditory features;  600512; LGI1
Epilepsy, progressive myoclonic 1;  254800; CSTB
Epilepsy, progressive myoclonic 1B;  612437; PRICKLE1
Epilepsy, progressive myoclonic 2B;  254780; NHLRC1
Epilepsy, progressive myoclonic 3;  611726; KCTD7
Epilepsy, pyridoxine-dependent;  266100; ALDH7A1
Epilepsy, severe myoclonic, of infancy;  607208; SCN1A
Epilepsy, X-linked, with variable learning disabilities and behavior disorders;  300491; SYN1
Epileptic encephalopathy, early infantile, 1;  308350; ARX
Epileptic encephalopathy, early infantile, 2;  300672; CDKL5
Epileptic encephalopathy, early infantile, 4;  612164; STXBP1
Epileptic encephalopathy, early infantile, 5;  613477; SPTAN1
Epileptic encephalopathy, Lennox-Gastaut type;  606369; MAPK10
Epiphyseal dysplasia, multiple 1;  132400; COMP
Epiphyseal dysplasia, multiple, 2;  600204; COL9A2
Epiphyseal dysplasia, multiple, 3;  600969; COL9A3
Epiphyseal dysplasia, multiple, 4;  226900; SLC26A2
Epiphyseal dysplasia, multiple, 5;  607078; MATN3
Epiphyseal dysplasia, multiple, with myopia and deafness;  132450; COL2A1
Episodic ataxia, type 2;  108500; CACNA1A
Episodic ataxia, type 6;  612656; SLC1A3
Episodic ataxia/myokymia syndrome;  160120; KCNA1
Epstein syndrome;  153650; MYH9
Erythermalgia, primary;  133020; SCN9A
Erythrocyte lactate transporter defect;  245340; SLC16A1
Erythrocytosis, familial, 3;  609820; EGLN1
Erythrocytosis, familial, 4;  611783; EPAS1
Erythrokeratodermia variabilis et progressiva;  133200; GJB3
Erythrokeratodermia variabilis with erythema gyratum repens;  133200; GJB4
Escobar syndrome;  265000; CHRNG
Esophageal cancer;  133239; DLEC1
Esophageal cancer, somatic;  133239; TGFBR2
Esophageal carcinoma, somatic;  133239; RNF6
Esophageal squamous cell carcinoma;  133239; 40513
Esophageal squamous cell carcinoma;  133239; LZTS1
Esophageal squamous cell carcinoma;  133239; WWOX
Ethylmalonic encephalopathy;  602473; ETHE1
Ewing sarcoma;  612219; EWSR1
Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis;  612714; COX4I2
Exostoses, multiple, type 1;  133700; EXT1
Exostoses, multiple, type 2;  133701; EXT2
Exudative vitreoretinopathy 4;  601813; LRP5
Exudative vitreoretinopathy 5;  613310; TSPAN12
Exudative vitreoretinopathy;  133780; FZD4
Exudative vitreoretinopathy, X-linked;  305390; NDP
Fabry disease;  301500; GLA
Fabry disease, cardiac variant;  301500; GLA
Factor V and factor VIII, combined deficiency of;  227300; MCFD2
Factor V deficiency;  227400; F5
Factor XI deficiency, autosomal dominant;  612416; F11
Factor XI deficiency, autosomal recessive;  612416; F11
Factor XII deficiency;  234000; F12
Factor XIIIA deficiency;  613225; F13A1
Factor XIIIB deficiency;  613235; F13B
Failure of tooth eruption, primary;  125350; PTHR1
Familial cold autoinflammatory syndrome 2;  611762; NALP12
Familial Mediterranean fever, AD;  134610; MEFV
Familial Mediterranean fever, AR;  249100; MEFV
Fanconi anemia, complementation group 0;  613390; RAD51C
Fanconi anemia, complementation group A;  227650; FANCA
Fanconi anemia, complementation group B;  300514; FAAP95
Fanconi anemia, complementation group D1;  605724; BRCA2
Fanconi anemia, complementation group I;  609053; FANCI
Fanconi anemia, complementation group J;  609054; BRIP1
Fanconi anemia, complementation group N;  610832; PALB2
Fanconi renotubular syndrome 2;  613388; SLC34A1
Fanconi–Bickel syndrome;  227810; SLC2A2
Farber lipogranulomatosis;  228000; ASAH1
Fatty liver, acute, of pregnancy;  609016; HADHA
Febrile convulsions, familial, 3A;  604403; SCN1A
Febrile convulsions, familial, 3B;  604403; SCN9A
Febrilel, convulsions, familial;  611277; GABRG2
Fechtner syndrome;  153640; MYH9
Feingold syndrome;  164280; MYCN
Fertile eunuch syndrome;  228300; GNRHR
Fetal akinesia deformation sequence;  208150; DOK7
Fetal akinesia deformation sequence;  208150; RAPSN
Fetal hemoglobin quantitative trait locus 1;  141749; HBG1
Fetal hemoglobin quantitative trait locus 1;  141749; HBG2
FG syndrome 2;  300321; FLNA
FG syndrome 4;  300422; CASK
Fibrodysplasia ossificans progressiva;  135100; ACVR1
Fibromatosis, gingival;  135300; SOS1
Fibromatosis, gingival, 2;  135300; GINGF2
Fibromatosis, juvenile hyaline;  228600; ANTXR2
Fibrosis of extraocular muscles, congenital, 1;  135700; KIF21A
Fibrosis of extraocular muscles, congenital, 2;  602078; PHOX2A
Fibrosis of extraocular muscles, congenital, 3A;  600638; TUBB3
Fibrosis of extraocular muscles, congenital, 3B;  135700; KIF21A
Fibular hypoplasia and complex brachydactyly;  228900; GDF5
Fish-eye disease;  136120; LCAT
Fletcher factor deficiency;  612423; KLKB1
Focal cortical dysplasia, Taylor balloon cell type;  607341; TSC1
Focal dermal hypoplasia;  305600; PORCN
Folate malabsorption, hereditary;  229050; SLC46A1
Follicle-stimulating hormone deficiency, isolated;  229070; FSHB
Foveal hyperplasia;  136520; PAX6
Foveomacular dystrophy, adult-onset, with choroidal neovascularization;  608161; PRPH2
Fragile X syndrome;  300624; FMR1
Fragile X tremor/ataxia syndrome;  300623; FMR1
Frank–ter Haar syndrome;  249420; SH3PXD2B
Fraser syndrome;  219000; FRAS1
Fraser syndrome;  219000; FREM2
Frasier syndrome;  136680; WT1
Friedreich's ataxia with retained reflexes;  229300; FXN
Friedreich's ataxia;  229300; FXN
Frontometaphyseal dysplasia;  305620; FLNA
Frontonasal dysplasia 2;  613451; ALX4
Frontonasal dysplasia 3;  613456; ALX1
Frontorhiny;  136760; ALX3
Frontotemporal lobar degeneration with ubiquitin-positive inclusions;  607485; GRN
Frontotemporal lobar degeneration, TARDBP-related;  612069; TARDBP
Fructose intolerance;  229600; ALDOB
Fructose-1,6-bisphosphatase deficiency;  229700; FBP1
Fucosidosis;  230000; FUCA1
Fuhrmann syndrome;  228930; WNT7A
Fumarase deficiency;  606812; FH
Fundus albipunctatus;  136880; RDH5
Fundus albipunctatus;  136880; RLBP1
Fundus flavimaculatus;  248200; ABCA4
GABA-transaminase deficiency;  613163; ABAT
Galactokinase deficiency with cataracts;  230200; GALK1
Galactose epimerase deficiency;  230350; GALE
Galactosemia;  230400; GALT
Galactosialidosis;  256540; CTSA
Gallbladder disease 1;  600803; ABCB4
Gallbladder disease 4;  611465; ABCG8
GAMT deficiency;  612736; GAMT
Gastric cancer, familial diffuse;  137215; CDH1
Gastric cancer, somatic;  137215; APC
Gastric cancer, somatic;  137215; CASP10
Gastric cancer, somatic;  137215; ERBB2
Gastric cancer, somatic;  137215; FGFR2
Gastric cancer, somatic;  137215; IRF1
Gastric cancer, somatic;  137215; KLF6
Gastric cancer, somatic;  137215; MUTYH
Gastric cancer, somatic;  137215; PIK3CA
Gastrointestinal stromal tumor, somatic;  606764; KIT
Gastrointestinal stromal tumor, somatic;  606764; PDGFRA
Gaucher disease, atypical;  610539; PSAP
Gaucher disease, perinatal lethal;  608013; GBA
Gaucher disease, type;  230800; GBA
Gaucher disease, type II;  230900; GBA
Gaucher disease, type III;  231000; GBA
Gaucher disease, type IIIC;  231005; GBA
Gaze palsy, horizontal, with progressive scoliosis;  607313; ROBO3
Geleophysic dysplasia;  231050; ADAMTSL2
Generalized epilepsy and paroxysmal dyskinesia;  609446; KCNMA1
Generalized epilepsy with febrile seizures plus;  604233; SCN1B
Germ cell tumors;  273300; KIT
Geroderma osteodysplasticum;  231070; SCYL1BP1
Gerstmann–Sträussler–Scheinker syndrome;  137440; PRNP
Ghosal syndrome;  231095; TBXAS1
Giant axonal neuropathy-1;  256850; GAN
Gillespie syndrome;  206700; PAX6
Gitelman syndrome;  263800; SLC12A3
Glanzmann thrombasthenia, type A;  273800; ITGA2B
Glaucoma 1, open angle, 1O;  613100; NTF4
Glaucoma 1, open angle, E;  137760; OPTN
Glaucoma 1, open angle, G;  609887; WDR36
Glaucoma 1A, primary open angle, juvenile-onset;  137750; MYOC
Glaucoma 1B, primary open angle, adult onset;  137760; GLC1B
Glaucoma 3, primary congenital, D;  613086; LTBP2
Glaucoma 3A, primary congenital;  231300; CYP1B1
Glaucoma, primary open angle, adult-onset;  137760; CYP1B1
Glaucoma, primary open angle, juvenile-onset;  137750; CYP1B1
Glioblastoma, somatic;  137800; ERBB2
Globozoospermia;  102530; GOPC
Globozoospermia;  102530; SPATA16
Glomerulocystic kidney disease with hyperuricemia and isosthenuria;  609886; UMOD
Glomerulopathy with fibronectin deposits 2;  601894; FN1
Glomerulosclerosis, focal segmental, 1;  603278; ACTN4
Glomerulosclerosis, focal segmental, 2;  603965; TRPC6
Glomerulosclerosis, focal segmental, 3;  607832; CD2AP
Glomerulosclerosis, focal segmental, 5;  613237; INF2
Glomuvenous malformations;  138000; GLML
Glucocorticoid deficiency 2;  607398; MRAP
Glucocorticoid deficiency, due to ACTH unresponsiveness;  202200; MC2R
Glucose-galactose malabsorption;  606824; SLC5A1
GLUT1 deficiency syndrome 1;  606777; SLC2A1
GLUT1 deficiency syndrome 2;  612126; SLC2A1
Glutamate formiminotransferase deficiency;  229100; FTCD
Glutamine deficiency, congenital;  610015; GLUL
Glutaricaciduria, type I;  231670; GCDH
Glutaricaciduria, type IIA;  231680; ETFA
Glutaricaciduria, type IIB;  231680; ETFB
Glutaricaciduria, type IIC;  231680; ETFDH
Glutathione synthetase deficiency;  266130; GSS
Glycerol kinase deficiency;  307030; GK
Glycine encephalopathy;  605899; AMT
Glycine encephalopathy;  605899; GCSH
Glycine encephalopathy;  605899; GLDC
Glycine N-methyltransferase deficiency;  606664; GNMT
Glycogen storage disease 0, muscle;  611556; GYS1
Glycogen storage disease Ib;  232220; SLC37A4
Glycogen storage disease Ic;  232240; SLC37A4
Glycogen storage disease Ic;  232240; SLC17A3
Glycogen storage disease II;  232300; GAA
Glycogen storage disease IIb;  300257; LAMP2
Glycogen storage disease IIIa;  232400; AGL
Glycogen storage disease IIIb;  232400; AGL
Glycogen storage disease IV;  232500; GBE1
Glycogen storage disease IXc;  613027; PHKG2
Glycogen storage disease of heart, lethal congenital;  261740; PRKAG2
Glycogen storage disease VII;  232800; PFKM
Glycogen storage disease X;  261670; PGAM2
Glycogen storage disease XI;  612933; LDHA
Glycogen storage disease XII;  611881; ALDOA
Glycogen storage disease XIII;  612932; ENO3
Glycogen storage disease XIV;  612934; PGM1
Glycogen storage disease XV;  613507; GYG1
Glycogen storage disease type 0;  240600; GYS2
Glycogen storage disease, type IXa1;  306000; PHKA2
Glycogen storage disease, type IXa2;  306000; PHKA2
Glycosylphosphatidylinositol deficiency;  610293; PIGM
GM1-gangliosidosis, type I;  230500; GLB1
GM1-gangliosidosis, type II;  230600; GLB1
GM1-gangliosidosis, type III;  230650; GLB1
GM2-gangliosidosis, AB variant;  272750; GM2A
GM2-gangliosidosis, several forms;  272800; HEXA
Gnathodiaphyseal dysplasia;  166260; ANO5
Goldberg–Shpritzen megacolon syndrome;  609460; KIAA1279
Gout, PRPS-related;  300661; PRPS1
GRACILE syndrome;  603358; BCS1L
Greenberg dysplasia;  215140; LBR
Greig cephalopolysyndactyly syndrome;  175700; GLI3
Griscelli syndrome type 1;  214450; MYO5A
Griscelli syndrome type 2;  607624; RAB27A
Griscelli syndrome type 3;  609227; MLPH
Growth hormone deficiency with pituitary anomalies;  182230; HESX1
Growth hormone deficiency, isolated, type IA;  262400; GH1
Growth hormone deficiency, isolated, type IB;  612781; GH1
Growth hormone deficiency, isolated, type IB;  612781; GHRHR
Growth hormone deficiency, isolated, type II;  173100; GH1
Growth hormone insensitivity with immunodeficiency;  245590; STAT5B
Growth retardation with deafness and mental retardation due to IGF1 deficiency;  608747; IGF1
Growth retardation, developmental delay, coarse facies, and early death;  612938; FTO
Guttmacher syndrome;  176305; HOXA13
Gyrate atrophy of choroid and retina with or without ornithinemia;  258870; OAT
Haddad syndrome;  209880; ASCL1
Hailey–Hailey disease;  169600; ATP2C1
Haim–Munk syndrome;  245010; CTSC
Hallermann–Streiff syndrome;  234100; GJA1
Hand-foot-uterus Syndrome;  140000; HOXA13
Harderoporphyria;  121300; CPOX
HARP syndrome;  607236; PANK2
Hartnup disorder;  234500; SLC6A19
Hawkinsinuria;  140350; HPD
Hay–Wells syndrome;  106260; TP63
HDL deficiency, type 2;  604091; ABCA1
Hearing loss, low-frequency sensorineural;  600965; WFS1
Heart block, nonprogressive;  113900; SCN5A
Heart block, progressive, type IA;  113900; SCN5A
Heinz body anemia;  140700; HBA2
Heinz body anemias, alpha-;  140700; HBA1
Heinz body anemias, beta-;  140700; HBB
HELLP syndrome, maternal, of pregnancy;  609016; HADHA
Hemangioma, capillary infantile, somatic;  602089; FLT4
Hemangioma, capillary infantile, somatic;  602089; KDR
Hematopoiesis, cyclic;  162800; ELANE
Hematuria, benign familial;  141200; COL4A3
Hemiplegic migraine, familial;  141500; CACNA1A
Hemochromatosis, type 2A;  602390; HJV
Hemochromatosis, type 2B;  613313; HAMP
Hemochromatosis, type 3;  604250; TFR2
Hemochromatosis, type 4;  606069; SLC40A1
Hemolytic anemia due to adenylate kinase deficiency;  612631; AK1
Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency;  230450; GCLC
Hemolytic anemia due to glutathione synthetase deficiency;  231900; GSS
Hemolytic anemia due to hexokinase deficiency;  235700; HK1
Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency;  613470; GPI
Hemolytic uremic syndrome, atypical, susceptibility to, 1;  235400; HF1
Hemophagocytic lymphohistiocytosis, familial, 2;  603553; PRF1
Hemophagocytic lymphohistiocytosis, familial, 3;  608898; UNC13D
Hemophagocytic lymphohistiocytosis, familial, 4;  603552; STX11
Hemophilia B;  306900; F9
Hemorrhagic diathesis due to \'antithrombin\' Pittsburgh;  613490; SERPINA1
Hemosiderosis, systemic, due to aceruloplasminemia;  604290; CP
Hennekam lymphangiectasia-lymphedema syndrome;  235510; CCBE1
Hepatic adenoma;  142330; HNF1A
Hepatic venoocclusive disease with immunodeficiency;  235550; SP110
Hepatocellular cancer;  114550; PDGFRL
Hepatocellular carcinoma;  114550; CTNNB1
Hepatocellular carcinoma;  114550; TP53
Hepatocellular carcinoma, childhood type;  114550; MET
Hepatocellular carcinoma, somatic;  114550; AXIN1
Hepatocellular carcinoma, somatic;  114550; CASP8
Hepatocellular carcinoma, somatic;  114550; PIK3CA
Hereditary hemorrhagic telangiectasia-1;  187300; ENG
Hereditary hemorrhagic telangiectasia-2;  600376; ACVRL1
Hereditary motor and sensory neuropathy VI;  601152; MFN2
Hereditary motor and sensory neuropathy, type IIc;  606071; TRPV4
Hermansky–Pudlak syndrome 1;  203300; HPS1
Hermansky–Pudlak syndrome 2;  608233; AP3B1
Hermansky–Pudlak syndrome 3;  203300; HPS3
Hermansky–Pudlak syndrome 4;  203300; HPS4
Hermansky–Pudlak syndrome 5;  203300; HPS5
Hermansky–Pudlak syndrome 6;  203300; HPS6
Hermansky–Pudlak syndrome 7;  203300; DTNBP1
Hermansky–Pudlak syndrome 8;  203300; BLOC1S3
Heterotaxy, visceral, 1, S-linke;  306955; ZIC3
Heterotaxy, visceral, 2, autosomal;  605376; CFC1
Heterotaxy, visceral, 5;  270100; NODAL
Heterotopia, periventricular;  300049; FLNA
Heterotopia, periventricular, ED variant;  300537; FLNA
Hirschsprung's disease;  142623; GDNF
Hirschsprung's disease;  142623; RET
Hirschsprung disease, short-segment;  142623; PMX2B
Histiocytoma, angiomatoid fibrous, somatic;  612160; CREB1
HMG-CoA synthase-2 deficiency;  605911; HMGCS2
Hodgkin's lymphoma;  236000; KLHDC8B
Holocarboxylase synthetase deficiency;  253270; HLCS
Holoprosencephaly-2;  157170; SIX3
Holoprosencephaly-3;  142945; SHH
Holoprosencephaly-4;  142946; TGIF
Holoprosencephaly-5;  609637; ZIC2
Holoprosencephaly-7;  610828; PTCH1
Holoprosencephaly-9;  610829; GLI2
Holt–Oram syndrome;  142900; TBX5
Homocystinuria due to MTHFR deficiency;  236250; MTHFR
Homocystinuria, B6-responsive and nonresponsive types;  236200; CBS
Homocystinuria, cblD type, variant 1;  277410; C2orf25
Homocystinuria-megaloblastic anemia, cbl E type;  236270; MTRR
Hoyeraal–Hreidarsson syndrome;  300240; DKC1
HPRT-related gout;  300323; HPRT1
Huntington's disease;  143100; HTT
Huntington disease-like 1;  603218; PRNP
Huntington disease-like 2;  606438; JPH3
Hutchinson–Gilford progeria syndrome;  176670; LMNA
Hyalinosis, infantile systemic;  236490; ANTXR2
Hydatidiform mole;  231090; NALP7
Hydranencephaly with abnormal genitalia;  300215; ARX
Hydrocephalus due to aqueductal stenosis;  307000; L1CAM
Hydrocephalus with congenital idiopathic intestinal pseudoobstruction;  307000; L1CAM
Hydrocephalus with Hirschsprung disease and cleft palate;  142623; L1CAM
Hydrolethalus syndrome;  236680; HYLS1
Hyperalphalipoproteinemia;  143470; CETP
Hyperbilirubinemia, familial transcient neonatal;  237900; UGT1A1
Hypercarotenemia and vitamin A deficiency, autosomal dominant;  115300; BCMO1
Hypercholanemia, familial;  607748; BAAT
Hypercholanemia, familial;  607748; EPHX1
Hypercholanemia, familial;  607748; TJP2
Hypercholesterolemia, due to ligand-defective apo B;  144010; APOB
Hypercholesterolemia, familial;  143890; LDLR
Hypercholesterolemia, familial, 3;  603776; PCSK9
Hypercholesterolemia, familial, autosomal recessive;  603813; LDLRAP1
Hypercholesterolemia, familial, modification of;  143890; APOA2
Hyperchylomicronemia, late-onset;  144650; APOA5
Hyperekplexia and epilepsy;  300607; ARHGEF9
Hyperekplexia;  149400; GPHN
Hyperekplexia;  149400; SLC6A5
Hyperekplexia, autosomal recessive;  149400; GLRB
Hypereosinophilic syndrome, idiopathic, resistant to imatinib;  607685; PDGFRA
Hyperferritinemia-cataract syndrome;  600886; FTL
Hyperfibrinolysis, familial, due to increased release of PLAT;  612348; PLAT
Hyperglycinuria;  138500; SLC36A2
Hyperglycinuria;  138500; SLC6A19
Hyperglycinuria;  138500; SLC6A20
Hyper-IgD syndrome;  260920; MVK
Hyper-IgE recurrent infection syndrome;  147060; STAT3
Hyper-IgE recurrent infection syndrome, autosomal recessive;  243700; DOCK8
Hyperinsulinemic hypoglycemia, familial, 1;  256450; ABCC8
Hyperinsulinemic hypoglycemia, familial, 2;  601820; KCNJ11
Hyperinsulinemic hypoglycemia, familial, 3;  602485; GCK
Hyperinsulinemic hypoglycemia, familial, 4;  609975; HADHSC
Hyperinsulinemic hypoglycemia, familial, 5;  609968; INSR
Hyperinsulinemic hypoglycemia, familial, 7;  610021; SLC16A1
Hyperinsulinism-hyperammonemia syndrome;  606762; GLUD1
Hyperkalemic periodic paralysis, type 2;  613345; SCN4A
Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations;  116860; CCM1
Hyperlipoproteinemia, type Ib;  207750; APOC2
Hyperlysinemia;  238700; AASS
Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency;  250850; MAT1A
Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome;  238970; SLC25A15
Hyperostosis, endosteal;  144750; LRP5
Hyperoxaluria, primary, type 1;  259900; AGXT
Hyperoxaluria, primary, type II;  260000; GRHPR
Hyperoxaluria, primary, type III;  613616; DHDPSL
Hyperparathyroidism, AD;  145000; MEN1
Hyperparathyroidism, familial primary;  145000; HRPT2
Hyperparathyroidism, neonatal;  239200; CASR
Hyperparathyroidism-jaw tumor syndrome;  145001; HRPT2
Hyperpehnylalaninemia, BH4-deficient, B;  233910; GCH1
Hyperphenylalaninemia, BH4-deficient, A;  261640; PTS
Hyperphenylalaninemia, BH4-deficient, C;  261630; QDPR
Hyperphenylalaninemia, BH4-deficient, D;  264070; PCBD
Hyperpigmentation, cutaneous, with hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, and hypogonadism;  612391; SLC29A3
Hyperpigmentation, familial progressive;  145250; KITLG
Hyperprolinemia, type I;  239500; PRODH
Hyperprolinemia, type II;  239510; ALDH4A1
Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy;  605115; NR3C2
Hypertension, essential;  145500; PNMT
Hypertension, essential;  145500; AGTR1
Hypertension, essential;  145500; PTGIS
Hyperthyroidism, familial gestational;  603373; TSHR
Hyperthyroidism, nonautoimmune;  609152; TSHR
Hypertrophic osteoarthropathy, primary, autosomal recessive;  259100; HPGD
Hyperuricemic nephropathy, familial juvenile 1;  162000; UMOD
Hyperuricemic nephropathy, familial juvenile 2;  613092; REN
Hypoaldosteronism, congenital, due to CMO I deficiency;  203400; CYP11B2
Hypoaldosteronism, congenital, due to CMO II deficiency;  610600; CYP11B2
Hypoalphalipoproteinemia;  604091; APOA1
Hypocalcemia, autosomal dominant;  146200; CASR
Hypocalciuric hypercalcemia, type I;  145980; CASR
Hypochondroplasia;  146000; FGFR3
Hypoglycemia of infancy, leucine-sensitive;  240800; ABCC8
Hypogonadism, hypogonadotropic;  146110; PROK2
Hypogonadotropic hypogonadism due to GNRH deficiency;  227200; GNRH1
Hypogonadotropic hypogonadism;  146110; CHD7
Hypogonadotropic hypogonadism;  146110; FGFR1
Hypogonadotropic hypogonadism;  146110; KISS1R
Hypogonadotropic hypogonadism;  146110; NELF
Hypogonadotropic hypogonadism;  146110; TAC3
Hypogonadotropic hypogonadism;  146110; TACR3
Hypokalemic periodic paralysis type 1;  170400; CACNA1S
Hypomagnesemia 4, renal;  611718; EGF
Hypomagnesemia with secondary hypocalcemia;  602014; TRPM6
Hypomagnesemia, primary;  248250; CLDN16
Hypomagnesemia, renal, with ocular involvement;  248190; CLDN19
Hypomagnesemia-2, renal;  154020; FXYD2
Hypomyelination, global cerebral;  612949; SLC25A12
Hypoparathyroidism, autosomal dominant;  146200; PTH
Hypoparathyroidism, autosomal recessive;  146200; PTH
Hypoparathyroidism, familial isolated;  146200; GCMB
Hypoparathyroidism, sensorineural deafness, and renal dysplasia;  146255; GATA3
Hypoparathyroidism-retardation-dysmorphism syndrome;  241410; TBCE
Hypophosphatasia, adult;  146300; ALPL
Hypophosphatasia, childhood;  241510; ALPL
Hypophosphatasia, infantile;  241500; ALPL
Hypophosphatemia, X-linked;  307800; PHEX
Hypophosphatemic rickets with hypercalciuria;  241530; SLC34A3
Hypophosphatemic rickets;  300554; CLCN5
Hypophosphatemic rickets, AR;  241520; DMP1
Hypophosphatemic rickets, autosomal dominant;  193100; FGF23
Hypophosphatemic rickets, autosomal recessive, 2;  613312; ENPP1
Hypoplastic left heart syndrome;  241550; GJA1
Hypoproteinemia, hypercatabolic;  241600; B2M
Hypospadias 1, X-linked;  300633; AR
Hypospadias 2, X-linked;  300758; MAMLD1
Hypothryoidism, congenital, nongoitrous 4;  275100; TSHB
Hypothyroidism, congenital nongoitrous, 5;  225250; NKX2E
Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia;  218700; PAX8
Hypothyroidism, congenital, nongoitrous;  275200; TSHR
Hypotrichosis and recurrent skin vesicles;  613102; DSC3
Hypotrichosis simplex of scalp;  146520; CDSN
Hypotrichosis, congenital, with juvenile macular dystrophy;  601553; CDH3
Hypotrichosis, hereditary, Marie Unna type, 1;  146550; HR
Hypotrichosis, localized, autosomal recessive 2;  604379; LIPH
Hypotrichosis, localized, autosomal recessive, 3;  611452; P2RY5
Hypotrichosis, localized, autosomal recessive;  607903; DSG4
Hypotrichosis-lymphedema-telangiectasia syndrome;  607823; SOX18
Hypouricemia, renal, 2;  612076; SLC2A9
Hypouricemia, renal;  220150; SLC22A12
Hystrix-like ichthyosis with deafness;  602540; GJB2
Ichthyosiform erythroderma, congenital;  242100; TGM1
Ichthyosiform erythroderma, congenital, nonbullous, 1;  242100; ALOX12B
Ichthyosiform erythroderma, congenital, nonbullous, 1;  242100; ALOXE3
Ichthyosis bullosa of Siemens;  146800; KRT2
Ichthyosis follicularis, atrichia, and photophobia syndrome;  308205; MBTPS2
Ichthyosis histrix, Curth-Macklin Palmoplantar keratoderma, nonepidermolytic;  600962; KRT1
Ichthyosis prematurity syndrome;  608649; SLC27A4
Ichthyosis vulgaris;  146700; FLG
Ichthyosis with confetti;  609165; KRT10
Ichthyosis with hypotrichosis;  610765; ST14
Ichthyosis, congenital, autosomal recessive;  612281; ICHYN
Ichthyosis, cyclic, with epidermolytic hyperkeratosis;  607602; KRT1
Ichthyosis, cyclic, with epidermolytic hyperkeratosis;  607602; KRT10
Ichthyosis, harlequin;  242500; ABCA12
Ichthyosis, lamellar 2;  601277; ABCA12
Ichthyosis, lamellar, 3;  604777; CYP4F22
Ichthyosis, lamellar, autosomal recessive;  242300; TGM1
Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis;  607626; CLDN1
Ichthyosis, X-linked;  308100; STS
Iminoglycinuria, digenic;  242600; SLC36A2
Iminoglycinuria, digenic;  242600; SLC6A19
Iminoglycinuria, digenic;  242600; SLC6A20
Immune dysfunction with T-cell inactivation due to calcium entry defect 1;  612782; ORAI1
Immune dysfunction, with T-cell inactivation due to calcium entry defect 2;  612783; STIM1
Immunodeficiency due to defect in CD3-zeta;  610163; CD247
Immunodeficiency due to defect in MAPBP-interacting protein;  610798; MAPBPIP
Immunodeficiency due to purine nucleoside phosphorylase deficiency;  613179; PNP
Immunodeficiency with hyper IgM, type 4;  608106; UNG
Immunodeficiency with hyper-IgM, type 2;  605258; AICDA
Immunodeficiency with hyper-IgM, type 3;  606843; TNFRSF5
Immunodeficiency, common variable, 1;  607594; ICOS
Immunodeficiency, common variable, 2;  240500; TNFRSF13B
Immunodeficiency, common variable, 3;  613493; CD19
Immunodeficiency, common variable, 4;  613494; TNFRSF13C
Immunodeficiency, common variable, 5;  613495; MS4A1
Immunodeficiency, common variable, 6;  613496; CD81
Immunodeficiency, hypogammaglobulinemia, and reduced B cells;  612692; CD79B
Immunodeficiency, isolated;  300584; IKBKG
Immunodeficiency, X-linked, with hyper-IgM;  308230; TNFSF5
Immunodeficiency–centromeric instability–facial anomalies syndrome;  242860; DNMT3B
Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked;  304790; FOXP3
Immunoglobulin A deficiency 2;  609529; TNFRSF13B
Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia;  167320; VCP
Inclusion body myopathy, autosomal recessive;  600737; GNE
Inclusion body myopathy-3;  605637; MYH2
Incontinentia pigmenti, type II;  308300; IKBKG
Infantile neuroaxonal dystrophy 1;  256600; PLA2G6
Inflammatory bowel disease 25;  612567; CRFB4
Insensitivity to pain, channelopathy-associated;  243000; SCN9A
Insensitivity to pain, congenital, with anhidrosis;  256800; NTRK1
Insomnia, fatal familial;  600072; PRNP
Insulin resistance, severe, digenic;  604367; PPARG
Insulin resistance, severe, digenic;  604367; PPP1R3A
Insulin-like growth factor I, resistance to;  270450; IGF1R
Interleukin 1 receptor antagonist deficiency;  612852; IL1RN
Interleukin-2 receptor, alpha chain, deficiency of;  606367; IL2RA
Intestinal pseudoobstruction, neuronal;  300048; FLNA
Intrinsic factor deficiency;  261000; GIF
Invasive pneumococcal disease, recurrent isolated, 1;  610799; IRAK4
IRAK4 deficiency;  607676; IRAK4
Iridogoniodysgenesis, type 1;  601631; FOXC1
Iridogoniodysgenesis, type 2;  137600; PITX2
Iris hypoplasia and glaucoma;  601631; FOXC1
Iron-refractory iron deficiency anemia;  206200; TMPRSS6
Isobutyryl-coenzyme A dehydrogenase deficiency;  611283; ACAD8
Isovaleric acidemia;  243500; IVD
IVIC syndrome;  147750; SALL4
Jackson–Weiss syndrome;  123150; FGFR1
Jackson–Weiss syndrome;  123150; FGFR2
Jalili syndrome;  217080; CNNM4
Jensen syndrome;  311150; TIMM8A
Jervell and Lange-Nielsen syndrome 2;  612347; KCNE1
Jervell and Lange-Nielsen syndrome;  220400; KCNQ1
Johanson–Blizzard syndrome;  243800; UBR1
Joubert syndrome 1;  213300; INPP5E
Joubert syndrome 10;  300804; OFD1
Joubert syndrome 2;  608091; TMEM216
Joubert syndrome 4;  609583; NPHP1
Joubert syndrome 5;  610188; CEP290
Joubert syndrome 6;  610688; TMEM67
Joubert syndrome 7;  611560; RPGRIP1L
Joubert syndrome 8;  612291; ARL13B
Joubert syndrome 9;  612285; CC2D2A
Joubert syndrome-3;  608629; AHI1
Juvenile polyposis syndrome, infantile form;  174900; BMPR1A
Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome;  175050; MADH4
Kallmann syndrome 2;  147950; FGFR1
Kallmann syndrome 3;  244200; PROKR2
Kallmann syndrome 4;  610628; PROK2
Kallmann syndrome 5;  612370; CHD7
Kallmann syndrome 6;  612702; FGF8
Kanzaki disease;  609242; NAGA
Karak syndrome;  610217; PLA2G6
Kenny–Caffey syndrome-1;  244460; TBCE
Keratitis;  148190; PAX6
Keratitis–ichthyosis–deafness syndrome;  148210; GJB2
Keratoconus;  148300; VSX1
Keratoderma, palmoplantar, with deafness;  148350; GJB2
Keratosis follicularis spinulosa decalvans;  308800; SAT1
Keratosis linearis with ichthyosis congenita and sclerosing keratoderma;  601952; POMP
Keratosis palmoplantaris striata I;  148700; DSG1
Keratosis palmoplantaris striata II;  612908; DSP
Keratosis palmoplantaris striata III;  607654; KRT1
Keratosis, seborrheic, somatic;  182000; PIK3CA
Keutel syndrome;  245150; MGP
Kindler syndrome;  173650; KIND1
Kleefstra syndrome;  610253; EHMT1
Klippel–Feil syndrome, autosomal dominant;  118100; GDF6
Kniest dysplasia;  156550; COL2A1
Knobloch syndrome, type 1;  267750; COL18A1
Kowarski syndrome;  262650; GH1
Krabbe disease;  245200; GALC
Krabbe disease, atypical;  611722; PSAP
L-2-hydroxyglutaric aciduria;  236792; L2HGDH
Lactase deficiency, congenital;  223000; LCT
Lactase persistence/nonpersistence;  223100; MCM6
Lactic acidosis, fatal infantile;  245400; SUCLG1
Lacticacidemia due to PDX1 deficiency;  245349; PDX1
LADD syndrome;  149730; FGF10
LADD syndrome;  149730; FGFR3
Laing distal myopathy;  160500; MYH7
Langer mesomelic dysplasia;  249700; SHOX
Langer mesomelic dysplasia;  249700; SHOXY
Laron dwarfism;  262500; GHR
Larsen syndrome;  150250; FLNB
Laryngoonychocutaneous syndrome;  245660; LAMA3
Lathosterolosis;  607330; SC5DL
LCHAD deficiency;  609016; HADHA
Leber congenital amaurosis 1;  204000; GUCY2D
Leber congenital amaurosis 10;  611755; CEP290
Leber congenital amaurosis 12;  610612; RD3
Leber congenital amaurosis 13;  612712; RDH12
Leber congenital amaurosis 14;  613341; LRAT
Leber congenital amaurosis 2;  204100; RPE65
Leber congenital amaurosis 3;  604232; SPATA7
Leber congenital amaurosis 4;  604393; AIPL1
Leber congenital amaurosis 5;  604537; LCA5
Left ventricular noncompaction 1, with or without congenital heart defects;  604169; DTNA
Left ventricular noncompaction 3, with or without dilated cardiomyopathy;  601493; LDB3
Left ventricular noncompaction 4;  613424; ACTC1
Left ventricular noncompaction 5;  613426; MYH7
Left ventricular noncompaction 6;  601494; TNNT2
Left ventricular noncompaction, X-linked;  300183; TAZ
Legius syndrome;  611431; SPRED1
Leigh syndrome due to cytochrome c oxidase deficiency;  256000; COX15
Leigh syndrome due to mitochondrial complex I deficiency;  256000; C8orf38
Leigh syndrome due to mitochondrial complex I deficiency;  256000; NDUFA2
Leigh syndrome;  256000; BCS1L
Leigh syndrome;  256000; DLD
Leigh syndrome;  256000; NDUFS3
Leigh syndrome;  256000; NDUFS4
Leigh syndrome;  256000; NDUFS7
Leigh syndrome;  256000; NDUFS8
Leigh syndrome;  256000; NDUFV1
Leigh syndrome;  256000; SDHA
Leigh syndrome, due to COX deficiency;  256000; SURF1
Leigh syndrome, French-Canadian type;  220111; LRPPRC
Leigh syndrome, X-linked;  308930; PDHA1
Leiomyomatosis and renal cell cancer;  605839; FH
Leiomyomatosis, diffuse, with Alport syndrome;  308940; COL4A6
LEOPARD syndrome 2;  611554; RAF1
Leopard syndrome;  151100; PTPN11
Leprechaunism;  246200; INSR
Léri–Weill dyschondrosteosis;  127300; SHOX
Leri–Weill dyschondrosteosis;  127300; SHOXY
Lesch–Nyhan syndrome;  300322; HPRT1
Lethal congenital contractural syndrome 2;  607598; ERBB3
Lethal congenital contractural syndrome 3;  611369; PIP5K1C
Lethal congenital contracture syndrome 1;  253310; GLE1
Leukemia, acute lymphocytic;  613065; BCR
Leukemia, acute myelogenous;  601626; AMLCR2
Leukemia, acute myelogenous;  601626; GMPS
Leukemia, acute myelogenous;  601626; JAK2
Leukemia, acute myeloid;  601626; MLF1
Leukemia, acute myeloid;  601626; NSD1
Leukemia, acute myeloid;  601626; SH3GL1
Leukemia, acute myeloid;  601626; AF10
Leukemia, acute myeloid;  601626; ARHGEF12
Leukemia, acute myeloid;  601626; CEBPA
Leukemia, acute myeloid;  601626; FLT3
Leukemia, acute myeloid;  601626; KIT
Leukemia, acute myeloid;  601626; LPP
Leukemia, acute myeloid;  601626; NPM1
Leukemia, acute myeloid;  601626; NUP214
Leukemia, acute myeloid;  601626; PICALM
Leukemia, acute myeloid;  601626; RUNX1
Leukemia, acute myeloid;  601626; WHSC1L1
Leukemia, acute myeloid, somatic;  601626; ETV6
Leukemia, acute promyelocytic;  612376; RARA
Leukemia, chronic myeloid;  608232; BCR
Leukemia, juvenile myelomonocytic;  607785; ARHGAP26
Leukemia, juvenile myelomonocytic;  607785; NF1
Leukemia, juvenile myelomonocytic;  607785; PTPN11
Leukemia, megakaryoblastic, of Down syndrome;  190685; GATA1
Leukemia, megakaryoblastic, with or without Down syndrome;  190685; GATA1
Leukocyte adhesion deficiency;  116920; ITGB2
Leukocyte adhesion deficiency, type III;  612840; KIND3
Leukodystrophy, adult-onset, autosomal dominant;  169500; LMNB1
Leukodystrophy, dysmyelinating, and spastic paraparesis with or without dystonia;  612443; FA2H
Leukodystrophy, hypomyelinating, 2;  608804; GJC2
Leukodystrophy, hypomyelinating, 4;  612233; HSPD1
Leukodystrophy, hypomyelinating, 5;  610532; FAM126A
Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation;  611105; DARS2
Leukoencephalopathy with vanishing white matter;  603896; EIF2B1
Leukoencephalopathy with vanishing white matter;  603896; EIF2B2
Leukoencephalopathy with vanishing white matter;  603896; EIF2B3
Leukoencephalopathy with vanishing white matter;  603896; EIF2B5
Leukoencephalopathy, cystic, without megalencephaly;  612951; RNASET2
Leukoencephaly with vanishing white matter;  603896; EIF2B4
Leydig cell adenoma, somatic, with precocious puberty;  176410; LHCGR
Leydig cell hypoplasia with hypergonadotropic hypogonadism;  238320; LHCGR
Leydig cell hypoplasia with pseudohermaphroditism;  238320; LHCGR
Lhermitte–Duclos syndrome;  158350; PTEN
Liddle syndrome;  177200; SCNN1B
Liddle syndrome;  177200; SCNN1G
Li–Fraumeni syndrome;  151623; CDKN2A
Li–Fraumeni syndrome;  151623; TP53
Li–Fraumeni syndrome;  609265; CHEK2
Li–Fraumeni-like syndrome;  151623; TP53
LIG4 syndrome;  606593; LIG4
Limb-mammary syndrome;  603543; TP63
Lipase deficiency, combined;  246650; LMF1
Lipodystrophy, congenital generalized, type 1;  608594; AGPAT2
Lipodystrophy, congenital generalized, type 2;  269700; BSCL2
Lipodystrophy, congenital generalized, type 3;  612526; CAV1
Lipodystrophy, congenital generalized, type 4;  613327; PTRF
Lipodystrophy, familial partial;  151660; LMNA
Lipodystrophy, familial partial, type 3;  604367; PPARG
Lipodystrophy, partial, acquired;  608709; LMNB2
Lipoid adrenal hyperplasia;  201710; STAR
Lipoid congenital adrenal hyperplasia;  201710; CYP11A
Lipoid proteinosis;  247100; ECM1
Lipoprotein glomerulopathy;  611771; APOE
Lipoprotein lipase deficiency;  238600; LPL
Lissencephaly 3;  611603; TUBA1A
Lissencephaly syndrome, Norman–Roberts type;  257320; RELN
Lissencephaly, X-linked 2;  300215; ARX
Lissencephaly, X-linked;  300067; DCX
Lissencephaly-1;  607432; PAFAH1B1
Liver failure, acute infantile;  613070; TRMU
Loeys–Dietz syndrome, type 1A;  609192; TGFBR1
Loeys–Dietz syndrome, type 1B;  610168; TGFBR2
Loeys–Dietz syndrome, type 2A;  608967; TGFBR1
Loeys–Dietz syndrome, type 2B;  610380; TGFBR2
Long QT syndrome 12;  612955; SNT1
Long QT syndrome 13;  613485; KCNJ5
Long QT syndrome-1;  192500; KCNQ1
Long QT syndrome-10;  611819; SCN4B
Long QT syndrome-11;  611820; AKAP9
Long QT syndrome-3;  603830; SCN5A
Long QT syndrome-4;  600919; ANK2
Long QT syndrome-7;  170390; KCNJ2
Long QT syndrome-9;  611818; CAV3
Lowe syndrome;  309000; OCRL
Lujan–Fryns syndrome;  309520; MED12
Lung cancer;  211980; DLEC1
Lung cancer;  211980; RASSF1
Lung cancer;  211980; KRAS
Lung cancer;  211980; PPP2R1B
Lung cancer;  211980; SLC22A1L
Lung cancer, somatic;  211980; MAP3K8
Luteinizing hormone resistance, female;  238320; LHCGR
Lymphangioleiomyomatosis;  606690; TSC1
Lymphangioleiomyomatosis, somatic;  606690; TSC2
Lymphedema, hereditary I;  153100; FLT4
Lymphedema, hereditary, IC;  613480; GJC2
Lymphedema–distichiasis syndrome with renal disease and diabetes mellitus;  153400; FOXC2
Lymphedema–distichiasis syndrome;  153400; FOXC2
Lymphoma, non-Hodgkin;  605027; PRF1
Lymphoma, non-Hodgkin, somatic;  605027; RAD54L
Lymphoproliferative syndrome, EBV-associated, autosomal, 1;  613011; ITK
Lymphoproliferative syndrome, X-linked, 2;  300635; BIRC4
Lymphoproliferative syndrome, X-linked;  308240; SH2D1A
Lysinuric protein intolerance;  222700; SLC7A7
Lysosomal acid phosphatase deficiency;  200950; ACP2
Lysyl hydroxylase 3 deficiency;  612394; PLOD3
Machado–Joseph disease;  109150; ATXN3
Macrocephaly, alopecia, cutis laxa, and scoliosis;  613075; RIN2
Macrocephaly/autism syndrome;  605309; PTEN
Macrocytic anemia, refractory, due to 5q deletion, somatic;  153550; RPS14
Macrothrombocytopenia and progressive sensorineural deafness;  600208; MYH9
Macrothrombocytopenia;  300367; GATA1
Macrothrombocytopenia, autosomal dominant, TUBB1-related;  613112; TUBB1
Macular corneal dystrophy;  217800; CHST6
Macular degeneration, age-related, 11;  611953; CST3
Macular degeneration, age-related, 2;  153800; ABCA4
Macular degeneration, age-related, 3;  608895; FBLN5
Macular degeneration juvenile;  248200; CNGB3
Macular dystrophy, autosomal dominant, chromosome 6-linked;  600110; ELOVL4
Macular dystrophy, patterned;  169150; PRPH2
Macular dystrophy, retinal, 2;  608051; PROM1
Macular dystrophy, vitelliform;  608161; PRPH2
Majeed syndrome;  609628; LPIN2
Major depressive disorder 1;  608516; MDD1
Major depressive disorder 2;  608516; MDD2
Male infertility with large-headed, multiflagellar, polyploid spermatozoa;  243060; STK13
Male infertility, nonsyndromic, autosomal recessive;  612997; CATSPER1
Malonyl-CoA decarboxylase deficiency;  248360; MLYCD
Mandibuloacral dysplasia with type B lipodystrophy;  608612; ZMPSTE24
Mandibuloacral dysplasia;  248370; LMNA
Mannosidosis, alpha-, types I and II;  248500; MAN2B1
Mannosidosis, beta;  248510; MANBA
Maple syrup urine disease, type Ia;  248600; BCKDHA
Maple syrup urine disease, type Ib;  248600; BCKDHB
Maple syrup urine disease, type II;  248600; DBT
Maple syrup urine disease, type III;  248600; DLD
Marfan syndrome;  154700; FBN1
Marinesco–Sjögren syndrome;  248800; SIL1
Maroteaux–Lamy syndrome, several forms;  253200; ARSB
Marshall syndrome;  154780; COL11A1
Martsolf syndrome;  212720; RAB3GAP2
MASA syndrome;  303350; L1CAM
MASS syndrome;  604308; FBN1
Mast syndrome;  248900; ACP33
Maturity-onset diabetes of the young 6;  606394; NEUROD1
Maturity-onset diabetes of the young, type 10;  613370; INS
Maturity-onset diabetes of the young, type 11;  613375; BLK
Maturity-onset diabetes of the young, type IX;  612225; PAX4
Maturity-onset diabetes of the young, type VII;  610508; KLF11
Maturity-onset diabetes of the young, type VIII;  609812; CEL
May–Hegglin anomaly;  155100; MYH9
McArdle disease;  232600; PYGM
McCune–Albright syndrome;  174800; GNAS
McKusick–Kaufman syndrome;  236700; MKKS
Meacham syndrome;  608978; WT1
Meckel syndrome 7;  267010; NPHP3
Meckel syndrome type 4;  611134; CEP290
Meckel syndrome, type 1;  249000; MKS1
Meckel syndrome, type 3;  607361; TMEM67
Meckel syndrome, type 5;  611561; RPGRIP1L
Meckel syndrome, type 6;  612284; CC2D2A
Medullary cystic kidney disease 2;  603860; UMOD
Medullary thyroid carcinoma;  155240; RET
Medullary thyroid carcinoma, familial;  155240; NTRK1
Medulloblastoma;  155255; PTCH2
Medulloblastoma, desmoplastic;  155255; SUFU
Meesmann corneal dystrophy;  122100; KRT12
Meesmann corneal dystrophy;  122100; KRT3
Megalencephalic leukoencephalopathy with subcortical cysts;  604004; MLC1
Megaloblastic anemia-1, Finnish type;  261100; CUBN
Megaloblastic anemia-1, Norwegian type;  261100; AMN
Melanoma and neural system tumor syndrome;  155755; CDKN2A
Melanoma;  609048; CDK4
Melanoma, cutaneous malignant, 2;  155601; CDKN2A
Meleda disease;  248300; SLURP1
Melnick–Needles syndrome;  309350; FLNA
Melorheostosis with osteopoikilosis;  155950; LEMD3
Membranoproliferative glomerulonephritis with CFH deficiency;  609814; HF1
Meningioma;  607174; MN1
Meningioma, NF2-related, somatic;  607174; NF2
Menkes disease;  309400; ATP7A
Mental retardation and microcephaly with pontine and cerebellar hypoplasia;  300749; CASK
Mental retardation in cri-du-chat syndrome;  123450; CTNND2
Mental retardation syndrome, X-linked, Cabezas type;  300354; CUL4B
Mental retardation syndrome, X-linked, Siderius type;  300263; PHF8
Mental retardation, autosomal dominant 1;  156200; MBD5
Mental retardation, autosomal dominant 3;  612580; CDH15
Mental retardation, autosomal dominant 4;  612581; KIRREL3
Mental retardation, autosomal dominant 5;  612621; SYNGAP
Mental retardation, autosomal recessive 1;  249500; PRSS12
Mental retardation, autosomal recessive 13;  613192; TRAPPC9
Mental retardation, autosomal recessive 2A;  607417; CRBN
Mental retardation, autosomal recessive 3;  608443; CC2D1A
Mental retardation, autosomal recessive 7;  611093; TUSC3
Mental retardation, autosomal recessive, 6;  611092; GRIK2
Mental retardation, FRA12A type;  136630; DIP2B
Mental retardation, joint hypermobility and skin laxity, with or without metabolic abnormalities;  612652; PYCS
Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations;  613443; MEF2C
Mental retardation, truncal obesity, retinal dystrophy, and micropenis;  610156; INPP5E
Mental retardation, X-linked 1;  309530; IQSEC2
Mental retardation, X-linked 17/31, microduplication;  300705; HSD17B10
Mental retardation, X-linked 30;  300558; PAK3
Mental retardation, X-linked 36/43/54;  300419; ARX
Mental retardation, X-linked 45;  300498; ZNF81
Mental retardation, X-linked 58;  300210; TM4SF2
Mental retardation, X-linked 59;  300630; AP1S2
Mental retardation, X-linked 93;  300659; BRWD3
Mental retardation, X-linked 94;  300699; GRIA3
Mental retardation, X-linked 95;  300716; MAGT1
Mental retardation, X-linked nonspecific;  309541; GDI1
Mental retardation, X-linked nonspecific, 63;  300387; ACSL4
Mental retardation, X-linked nonspecific, type 46;  300436; ARHGEF6
Mental retardation, X-linked syndromic 10;  300220; HSD17B10
Mental retardation, X-linked syndromic, Christianson type;  300243; SLC9A6
Mental retardation, X-linked syndromic, Turner type;  300706; HUWE1
Mental retardation, X-linked, 21/34;  300143; IL1RAPL1
Mental retardation, X-linked;  300495; NLGN4
Mental retardation, X-linked, FRAXE type;  309548; AFF2
Mental retardation, X-linked, Lubs type;  300260; MECP2
Mental retardation, X-linked, Snyder-Robinson type;  309583; SMS
Mental retardation, X-linked, syndromic 13;  300055; MECP2
Mental retardation, X-linked, syndromic 14;  300676; UPF3B
Mental retardation, X-linked, syndromic, JARID1C-related;  300534; KDM5C
Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance;  300486; OPHN1
Mental retardation, X-linked, with epilepsy;  300423; ATP6AP2
Mental retardation, X-linked, with isolated growth hormone deficiency;  300123; SOX3
Mental retardation, X-linked, with or without epilepsy;  300802; SYP
Mental retardation, X-linked, ZDHHC9-related;  300799; ZDHHC9
Mental retardation, X-linked-72;  300271; RAB39B
Mental retardation, X-linked-9;  309549; FTSJ1
Mental retardation, X-linked-91;  300577; ZDHHC15
Mental retardation-hypotonic facies syndrome, X-linked, 2;  300639; CUL4B
Mental retardation-hypotonic facies syndrome, X-linked;  309580; ATRX
Mephenytoin poor metabolizer;  609535; CYP2C
Metachondromatosis;  156250; PTPN11
Metachromatic leukodystrophy due to SAP-b deficiency;  249900; PSAP
Metachromatic leukodystrophy;  250100; ARSA
Metaphyseal anadysplasia 1;  602111; MMP13
Metaphyseal anadysplasia 2;  613073; MMP9
Metaphyseal chondrodysplasia, Murk Jansen type;  156400; PTHR1
Metaphyseal dysplasia without hypotrichosis;  250460; RMRP
Metatropic dysplasia;  156530; TRPV4
Methemoglobinemia, type I;  250800; CYB5R3
Methemoglobinemia, type II;  250800; CYB5R3
Methemoglobinemia, type IV;  250790; CYB5A
Methionine adenosyltransferase deficiency, autosomal recessive;  250850; MAT1A
Methylcobalamin deficiency, cblG type;  250940; MTR
Methylmalonic aciduria and homocystinuria, cblC type;  277400; MMACHC
Methylmalonic aciduria and homocystinuria, cblD type;  277410; C2orf25
Methylmalonic aciduria and homocystinuria, cblF type;  277380; LMBRD1
Methylmalonic aciduria due to transcobalamin receptor defect;  613646; CD320
Methylmalonic aciduria, cblD type, variant 2;  277410; C2orf25
Methylmalonic aciduria, vitamin B12-responsive;  251100; MMAA
Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type;  251110; MMAB
Methylmalonyl-CoA epimerase deficiency;  251120; MCEE
Mevalonic aciduria;  610377; MVK
MHC class II deficiency, complementation group B;  209920; RFXANK
Micochondrial phosphate carrier deficiency;  610773; SLC25A3
Microcephalic osteodysplastic primordial dwarfism type II;  210720; PCNT
Microcephaly and digital abnormalities with normal intelligence;  602585; MYCN
Microcephaly, Amish type;  607196; SLC25A19
Microcephaly, autosomal recessive 1;  251200; MCPH1
Microcephaly, primary autosomal recessive, 2;  251200; MCPH2
Microcephaly, primary autosomal recessive, 3;  604804; CDK5RAP2
Microcephaly, primary autosomal recessive, 4;  251200; MCPH4
Microcephaly, primary autosomal recessive, 5, with or without simplified gyral pattern;  608716; ASPM
Microcephaly, primary autosomal recessive, 6;  608393; CEMPJ
Microcephaly, primary autosomal recessive, 7;  612703; STIL
Microcephaly, seizures, and developmental delay;  613402; PNKP
Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma;  193220; BEST1
Microphthalmia, isolated 2;  610093; CHX10
Microphthalmia, isolated 3;  611038; RAX
Microphthalmia, isolated 4;  613094; GDF6
Microphthalmia, isolated 5;  611040; MFRP
Microphthalmia, isolated, with cataract 2;  212550; SIX6
Microphthalmia, isolated, with cataract 4;  610426; CRYBA4
Microphthalmia, isolated, with coloboma 3;  610092; CHX10
Microphthalmia, isolated, with coloboma 5;  611638; SHH
Microphthalmia, syndromic 2;  300166; BCOR
Microphthalmia, syndromic 3;  206900; SOX2
Microphthalmia, syndromic 5;  610125; OTX2
Microphthalmia, syndromic 6;  607932; BMP4
Microphthalmia, syndromic 7;  309801; HCCS
Microphthalmia, syndromic 9;  601186; STRA6
Microtia, hearing impairment, and cleft palate;  612290; HOXA2
Microvillus inclusion disease;  251850; MYO5B
Migraine, familial basilar;  602481; ATP1A2
Migraine, familial hemiplegic, 2;  602481; ATP1A2
Migraine, familial hemiplegic, 3;  609634; SCN1A
Migraine, resistance to;  157300; EDNRA
Miller syndrome;  264750; DHODH
Minicore myopathy with external ophthalmoplegia;  255320; RYR1
Mirror movements, congenital;  157600; DCC
Mirror-image polydactyly;  135750; MIPOL1
Mismatch repair cancer syndrome;  276300; MLH1
Mismatch repair cancer syndrome;  276300; MSH2
Mismatch repair cancer syndrome;  276300; MSH6
Mismatch repair cancer syndrome;  276300; PMS2
Mitochondrial complex 1 deficiency;  252010; C20orf7
Mitochondrial complex I deficiency;  252010; NDUFA1
Mitochondrial complex I deficiency;  252010; NDUFA11
Mitochondrial complex I deficiency;  252010; NDUFAF2
Mitochondrial complex I deficiency;  252010; NDUFAF3
Mitochondrial complex I deficiency;  252010; NDUFAF4
Mitochondrial complex I deficiency;  252010; NDUFS1
Mitochondrial complex I deficiency;  252010; NDUFS2
Mitochondrial complex I deficiency;  252010; NDUFS4
Mitochondrial complex I deficiency;  252010; NDUFV1
Mitochondrial complex I deficiency;  252010; NDUFV2
Mitochondrial complex II deficiency;  252011; SDHAF1
Mitochondrial complex III deficiency;  124000; BCS1L
Mitochondrial complex III deficiency;  124000; UQCRB
Mitochondrial complex III deficiency;  124000; UQCRQ
Mitochondrial complex IV deficiency;  220110; FASTKD2
Mitochondrial DNA depletion syndrome, encephalomyopathic form, with methylmalonic aciduria;  612073; SUCLA2
Mitochondrial DNA depletion syndrome, encephalomyopathic form, with renal tubulopathy;  612075; RRM2B
Mitochondrial DNA depletion syndrome, hepatocerebral form;  251880; C10orf2
Mitochondrial DNA depletion syndrome, hepatocerebral form;  251880; MPV17
Mitochondrial DNA depletion syndrome, myopathic form;  609560; TK2
Mitochondrial DNA-depletion syndrome, hepatocerebral form;  251880; DGUOK
Mitochondrial myopathy and sideroblastic anemia;  600462; PUS1
Mitochondrial neurogastrointestinal encephalomyopathy syndrome;  603041; TYMP
Mitochondrial respiratory chain complex II deficiency;  252011; SDHA
Miyoshi muscular dystrophy 3;  613319; ANO5
Miyoshi myopathy;  254130; DYSF
MNGIE without leukoencephalopathy;  603041; POLG
MODY, type I;  125850; HNF4A
MODY, type II;  125851; GCK
MODY, type III;  600496; HNF1A
MODY, type IV;  606392; IPF1
Mohr–Tranebjærg syndrome;  304700; TIMM8A
Molybdenum cofactor deficiency, type A;  252150; MOCS1
Molybdenum cofactor deficiency, type B;  252150; MOCS2
Molybdenum cofactor deficiency, type C;  252150; GPHN
Monilethrix;  158000; KRT81
Monilethrix;  158000; KRT83
Monilethrix;  158000; KRT86
Mononeuropathy of the median nerve, mild;  613353; SH3TC2
Morning glory disc anomaly;  120430; PAX6
Morquio syndrome B;  253010; GLB1
Mosaic variegated aneuploidy syndrome;  257300; BUB1B
Mowat–Wilson syndrome;  235730; ZEB2
Muckle–Wells syndrome;  191900; NLRP3
Mucolipidosis II alpha/beta;  252500; GNPTAB
Mucolipidosis III alpha/beta;  252600; GNPTAB
Mucolipidosis III gamma;  252605; GNPTAG
Mucolipidosis IV;  252650; MCOLN1
Mucopolysaccharidosis Ih;  607014; IDUA
Mucopolysaccharidosis Ih/s;  607015; IDUA
Mucopolysaccharidosis Is;  607016; IDUA
Mucopolysaccharidosis IVA;  253000; GALNS
Mucopolysaccharidosis type IIID;  252940; GNS
Mucopolysaccharidosis type IX;  601492; HYAL1
Mucopolysaccharidosis VII;  253220; GUSB
Muenke syndrome;  602849; FGFR3
Muir–Torre syndrome;  158320; MLH1
Muir–Torre syndrome;  158320; MSH2
Mulibrey nanism;  253250; TRIM37
Mullerian aplasia and hyperandrogenism;  158330; WNT4
Multiple cutaneous and uterine leiomyomata;  150800; FH
Multiple endocrine neoplasia IIA;  171400; RET
Multiple endocrine neoplasia IIB;  162300; RET
Multiple endocrine neoplasia, type IV;  610755; CDKN1B
Multiple pterygium syndrome, lethal type;  253290; CHRNA1
Multiple pterygium syndrome, lethal type;  253290; CHRND
Multiple pterygium syndrome, lethal type;  253290; CHRNG
Multiple sulfatase deficiency;  272200; SUMF1
Multiple synostoses syndrome 3;  612961; FGF9
Muscle glycogenosis;  300559; PHKA1
Muscular dystrophy with epidermolysis bullosa simplex;  226670; PLEC1
Muscular dystrophy, congenital merosin-deficient;  607855; LAMA2
Muscular dystrophy, congenital, due to ITGA7 deficiency;  613204; ITGA7
Muscular dystrophy, congenital, due to partial LAMA2 deficiency;  607855; LAMA2
Muscular dystrophy, limb-girdle, type 1A;  159000; TTID
Muscular dystrophy, limb-girdle, type 1B;  159001; LMNA
Muscular dystrophy, limb-girdle, type 2A;  253600; CAPN3
Muscular dystrophy, limb-girdle, type 2B;  253601; DYSF
Muscular dystrophy, limb-girdle, type 2C;  253700; SGCG
Muscular dystrophy, limb-girdle, type 2D;  608099; SGCA
Muscular dystrophy, limb-girdle, type 2E;  604286; SGCB
Muscular dystrophy, limb-girdle, type 2F;  601287; SGCD
Muscular dystrophy, limb-girdle, type 2G;  601954; TCAP
Muscular dystrophy, limb-girdle, type 2H;  254110; TRIM32
Muscular dystrophy, limb-girdle, type 2J;  608807; TTN
Muscular dystrophy, limb-girdle, type 2L;  611307; ANO5
Muscular dystrophy, limb-girdle, type IC;  607801; CAV3
Muscular dystrophy, rigid spine, 1;  602771; SEPN1
Myasthenia, limb-girdle, familial;  254300; AGRN
Myasthenia, limb-girdle, familial;  254300; DOK7
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency;  608931; CHRNB1
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency;  608931; CHRNE
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency;  608931; MUSK
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency;  608931; RAPSN
Myasthenic syndrome, congenital, associated with episodic apnea;  254210; CHAT
Myasthenic syndrome, congenital, associated with facial dysmorphism and acetylcholine receptor deficiency;  608931; RAPSN
Myasthenic syndrome, fast-channel congenital;  608930; CHRNA1
Myasthenic syndrome, fast-channel congenital;  608930; CHRND
Myasthenic syndrome, fast-channel congenital;  608930; CHRNE
Myasthenic syndrome, slow-channel congenital;  601462; CHRNA1
Myasthenic syndrome, slow-channel congenital;  601462; CHRNB1
Myasthenic syndrome, slow-channel congenital;  601462; CHRND
Myasthenic syndrome, slow-channel congenital;  601462; CHRNE
Mycobacterial infection, atypical, familial disseminated;  209950; IFNGR1
Mycobacterial infection, atypical, familial disseminated;  209950; STAT1
Myelofibrosis, idiopathic;  254450; JAK2
Myeloperoxidase deficiency;  254600; MPO
Myeloproliferative disorder with eosinophilia;  131440; PDGFRB
Myoclonic epilepsy, severe, of infancy;  607208; GABRG2
Myoglobinuria, acute recurrent, autosomal recessive;  268200; LPIN1
Myokymia with neonatal epilepsy;  606437; KCNQ2
Myopathy due to CPT II deficiency;  255110; CPT2
Myopathy with lactic acidosis, hereditary;  255125; ISCU
Myopathy, actin, congenital, with excess of thin myofilaments;  161800; ACTA1
Myopathy, cardioskeletal, desmin-related, with cataract;  608810; CRYAB
Myopathy, centronuclear;  160150; DNM2
Myopathy, centronuclear;  160150; MYF6
Myopathy, centronuclear, autosomal recessive;  255200; BIN1
Myopathy, congenital, Compton-North;  612540; CNTN1
Myopathy, congenital, with fiber-type disproportion 1;  255310; ACTA1
Myopathy, desmin-related, cardioskeletal;  601419; DES
Myopathy, distal 2;  606070; MATR3
Myopathy, distal, with anterior tibial onset;  606768; DYSF
Myopathy, early-onset, with fatal cardiomyopathy;  611705; TTN
Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay;  613076; GFER
Myopathy, myofibrillar, BAG3-related;  612954; BAG3
Myopathy, myofibrillar, filamin C-related;  609524; FLNC
Myopathy, myofibrillar, ZASP-related;  609452; LDB3
Myopathy, myosin storage;  608358; MYH7
Myopathy, nemaline, 3;  161800; ACTA1
Myopathy, proximal, with early respiratory muscle involvement;  603689; TTN
Myopathy, reducing body, X-linked, childhood-onset;  300718; FHL1
Myopathy, reducing body, X-linked, severe early-onset;  300717; FHL1
Myopathy, spheroid body;  182920; TTID
Myopathy, X-linked, with postural muscle atrophy;  300696; FHL1
Myosclerosis, congenital;  255600; COL6A2
Myotilinopathy;  609200; TTID
Myotonia congenita, atypical, acetazolamide-responsive;  608390; SCN4A
Myotonia congenita, dominant;  160800; CLCN1
Myotonia congenita, recessive;  255700; CLCN1
Myotonic dystrophy;  160900; DMPK
Myotonic dystrophy, type 2;  602668; ZNF9
Myotubular myopathy, X-linked;  310400; MTM1
Myxoid liposarcoma;  613488; DDIT3
Myxoma, intracardiac;  255960; PRKAR1A
N syndrome;  310465; POLA
N-Acetylglutamate synthase deficiency;  237310; NAGS
Naegeli–Franceschetti–Jadassohn syndrome;  161000; KRT14
Nail–patella syndrome;  161200; LMX1B
Nance–Horan syndrome;  302350; NHS
Narcolepsy 1;  161400; HCRT
Nasopharyngeal carcinoma;  607107; TP53
Nasu–Hakola disease;  221770; TREM2
Nasu–Hakola disease;  221770; TYROBP
Naxos disease;  601214; JUP
Nemaline myopathy 1, autosomal dominant;  609284; TPM3
Nemaline myopathy 2, autosomal recessive;  256030; NEB
Nemaline myopathy 7;  610687; CFL2
Nemaline myopathy;  609285; TPM2
Nemaline myopathy, Amish type;  605355; TNNT1
Nephrogenic syndrome of inappropriate antidiuresis;  300539; AVPR2
Nephrolithiasis, type I;  310468; CLCN5
Nephrolithiasis/osteoporosis, hypophosphatemic, 1;  612286; SLC34A1
Nephrolithiasis/osteoporosis, hypophosphatemic, 2;  612287; SLC9A3R1
Nephronophthisis 1, juvenile;  256100; NPHP1
Nephronophthisis 2, infantile;  602088; INVS
Nephronophthisis 3;  604387; NPHP3
Nephronophthisis 4;  606966; NPHP4
Nephronophthisis 7;  611498; GLIS2
Nephropathy with pretibial epidermolysis bullosa and deafness;  609057; CD151
Nephrosis, congenital, with or without ocular abnormalities;  609049; LAMB2
Nephrotic syndrome, type 1;  256300; NPHS1
Nephrotic syndrome, type 2;  600995; PDCN
Nephrotic syndrome, type 3;  610725; PLCE1
Nephrotic syndrome, type 4;  256370; WT1
Netherton syndrome;  256500; SPINK5
Neural tube defect;  182940; VANGL1
Neuroblastoma;  256700; NME1
Neurodegeneration due to cerebral folate transport deficiency;  613068; FOLR1
Neurodegeneration with brain iron accumulation 1;  234200; PANK2
Neurodegeneration with brain iron accumulation 2B;  610217; PLA2G6
Neurodegeneration with brain iron accumulation 3;  606159; FTL
Neuroepithelioma;  612219; EWSR1
Neurofibromatosis, familial spinal;  162210; NF1
Neurofibromatosis type 1;  162200; NF1
Neurofibromatosis type 2;  101000; NF2
Neurofibromatosis-Noonan syndrome;  601321; NF1
Neuromuscular disease, congenital, with uniform type 1 fiber;  117000; RYR1
Neuronopathy, distal hereditary motor, type IIC;  613376; HSPB3
Neuronopathy, distal hereditary motor, type VI;  604320; IGHMBP2
Neuropathy, congenital hypomyelinating, 1;  605253; EGR2
Neuropathy, congenital hypomyelinating;  605253; MPZ
Neuropathy, distal hereditary motor, type IIA;  158590; HSPB8
Neuropathy, distal hereditary motor, type IIB;  608634; HSPB1
Neuropathy, distal hereditary motor, type V;  600794; BSCL2
Neuropathy, distal hereditary motor, type V;  600794; GARS
Neuropathy, distal hereditary motor, type VIIB;  607641; DCTN1
Neuropathy, hereditary sensory and autonomic, type 1;  162400; SPTLC1
Neuropathy, hereditary sensory and autonomic, type II;  201300; WNK1
Neuropathy, hereditary sensory and autonomic, type IIB;  613115; FAM134B
Neuropathy, hereditary sensory and autonomic, type V;  608654; NGFB
Neuropathy, hereditary sensory, with spastic paraplegia;  256840; CCT5
Neuropathy, hereditary sensory/autonomic, type IC;  613640; SPTLC2
Neuropathy, recurrent, with pressure palsies;  162500; PMP22
Neutral lipid storage disease with myopathy;  610717; PNPLA2
Neutropenia, nonimmune chronic idiopathic, of adults;  607847; GFI1
Neutropenia, severe congenital, autosomal dominant 1;  202700; ELANE
Neutropenia, severe congenital, autosomal dominant 2;  613107; GFI1
Neutropenia, severe congenital, autosomal recessive 3;  610738; HAX1
Neutropenia, severe congenital, autosomal recessive 4;  612541; G6PC3
Neutropenia, severe congenital, X-linked;  300299; WAS
Neutrophil immunodeficiency syndrome;  608203; RAC2
Neutrophilia, hereditary;  162830; CSF3R
Nevo syndrome;  601451; PLOD
Nevus, epidermal;  162900; PIK3CA
Nevus, epidermal, epidermolytic hyperkeratotic type;  600648; KRT10
Nevus, keratinocytic, nonepidermolytic;  162900; FGFR3
Newfoundland rod-cone dystrophy;  607476; RLBP1
Niemann–Pick disease, type A;  257200; SMPD1
Niemann–Pick disease, type B;  607616; SMPD1
Niemann–Pick disease, type C1;  257220; NPC1
Niemann–Pick disease, type C2;  607625; NPC2
Niemann–Pick disease type D;  257220; NPC1
Night blindness, congenital stationary, autosomal dominant 2;  163500; PDE6B
Night blindness, congenital stationary, autosomal dominant 3;  610444; GNAT1
Night blindness, congenital stationary, type 1;  310500; CSNB1
Night blindness, congenital stationary, type 1B;  257270; GRM6
Night blindness, congenital stationary, type 2B;  610427; CABP4
Night blindness, congenital stationary, type IC;  613216; TRPM1
Night blindness, congenital stationary, X-linked, type 2A;  300071; CACNA1F
Night blindness, congenital stationary, autosomal dominant 1;  610445; RHO
Nijmegen breakage syndrome;  251260; NBS1
Nijmegen breakage syndrome-like disorder;  613078; RAD50
Nonaka myopathy;  605820; GNE
Non-Hodgkin lymphoma, somatic;  605027; CASP10
Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in;  211980; EGFR
Nonsmall cell lung cancer, somatic;  211980; IRF1
Nonsmall cell lung cancer, somatic;  211980; PIK3CA
Noonan syndrome 1;  163950; PTPN11
Noonan syndrome 3;  609942; KRAS
Noonan syndrome 4;  610733; SOS1
Noonan syndrome 5;  611553; RAF1
Noonan syndrome 6;  613224; NRAS
Noonan-like syndrome with loose anagen hair;  607721; SHOC2
Norrie disease;  310600; NDP
Norum disease;  245900; LCAT
Nystagmus 1, congenital, X-linked;  310700; FRMD7
Nystagmus 6, congenital, X-linked;  300814; GPR143
Obesity with impaired prohormone processing;  600955; PCSK1
Obesity, adrenal insufficiency, and red hair due to POMC deficiency;  609734; POMC
Obesity, autosomal dominant;  601665; MC4R
Obesity, mild, early-onset;  601665; NR0B2
Obesity, severe;  601665; PPARG
Obesity, severe;  601665; SIM1
Occipital horn syndrome;  304150; ATP7A
Ocular albinism, type I, Nettleship-Falls type;  300500; GPR143
Oculoauricular syndrome;  612109; HMX1
Oculocutaneous albinism, type IV;  606574; SLC45A2
Oculodentodigital dysplasia;  164200; GJA1
Oculodentodigital dysplasia, autosomal recessive;  257850; GJA1
Oculopharyngeal muscular dystrophy;  164300; PABPN1
Odontohypophosphatasia;  146300; ALPL
Odontoonychodermal dysplasia;  257980; WNT10A
Ogden syndrome;  300855; NAA10
Oguchi disease-1;  258100; SAG
Oguchi disease-2;  613411; GRK1
OI type II;  166210; COL1A1
OI type III;  259420; COL1A1
OI type IV;  166220; COL1A1
Oligodontia-colorectal cancer syndrome;  608615; AXIN2
Omenn syndrome;  603554; DCLRE1C
Omenn syndrome;  603554; RAG1
Omenn syndrome;  603554; RAG2
Omodysplasia 1;  258315; GPC6
Opitz G syndrome, type I;  300000; MID1
Opitz–Kaveggia syndrome;  305450; MED12
Opremazole poor metabolizer;  609535; CYP2C
Optic atrophy 1;  165500; OPA1
Optic atrophy and cataract;  165300; OPA3
Optic atrophy and deafness;  125250; OPA1
Optic atrophy-7;  612989; TMEM126A
Optic nerve coloboma with renal disease;  120330; PAX2
Optic nerve hypoplasia and abnormalities of the central nervous system;  206900; SOX2
Optic nerve hypoplasia;  165550; PAX6
Oral-facial-digital syndrome 1;  311200; OFD1
Ornithine transcarbamylase deficiency;  311250; OTC
Orofacial cleft 11;  600625; BMP4
Orofacial cleft 5;  608874; MSX1
Orofacial cleft 6;  608864; IRF6
Orofacial cleft 7;  225060; HVEC
Orofacial cleft 8;  129400; TP63
Orthostatic intolerance;  604715; SLC6A2
Osseous heteroplasia, progressive;  166350; GNAS
Ossification of posterior longitudinal ligament of spine;  602475; ENPP1
Osteoarthritis with mild chondrodysplasia;  604864; COL2A1
Osteochondritis dissecans, short stature, and early-onset osteoarthritis;  165800; ACAN
Osteogenesis imperfecta, type I;  166200; COL1A1
Osteogenesis imperfecta, type II;  166210; COL1A2
Osteogenesis imperfecta, type IIB;  610854; CRTAP
Osteogenesis imperfecta, type III;  259420; COL1A2
Osteogenesis imperfecta, type IV;  166220; COL1A2
Osteogenesis imperfecta, type IX;  259440; PPIB
Osteogenesis imperfecta, type VI;  610698; FKBP10
Osteogenesis imperfecta, type VII;  610682; CRTAP
Osteogenesis imperfecta, type VIII;  610915; LEPRE1
Osteoglophonic dysplasia;  166250; FGFR1
Osteolysis, familial expansile;  174810; TNFRSF11A
Osteopathia striata with cranial sclerosis;  300373; FAM123B
Osteopetrosis, AD type I;  607634; LRP5
Osteopetrosis, autosomal dominant 2;  166600; CLCN7
Osteopetrosis, autosomal recessive 2;  259710; TNFSF11
Osteopetrosis, autosomal recessive 3, with renal tubular acidosis;  259730; CA2
Osteopetrosis, autosomal recessive 4;  611490; CLCN7
Osteopetrosis, autosomal recessive 5;  259720; OSTM1
Osteopetrosis, autosomal recessive 6;  611497; PLEKHM1
Osteopetrosis, autosomal recessive 7;  612301; TNFRSF11A
Osteopetrosis, recessive 1;  259700; TCIRG1
Osteopoikilosis;  166700; LEMD3
Osteoporosis, involutional;  166710; VDR
Osteoporosis-pseudoglioma syndrome;  259770; LRP5
Osteosarcoma;  259500; LOH18CR1
Osteosarcoma;  259500; RB1
Osteosarcoma;  259500; TP53
Osteosarcoma, somatic;  259500; CHEK2
Osteosclerosis;  144750; LRP5
Otofaciocervical syndrome;  166780; EYA1
Otopalatodigital syndrome, type I;  311300; FLNA
Otopalatodigital syndrome, type II;  304120; FLNA
Otospondylomegaepiphyseal dysplasia;  215150; COL11A2
Ovarian cancer;  167000; CTNNB1
Ovarian cancer, somatic;  604370; AKT1
Ovarian cancer, somatic;  604370; PIK3CA
Ovarian dysgenesis 1;  233300; FSHR
Ovarian dysgenesis 2;  300510; BMP15
Ovarian hyperstimulation syndrome;  608115; FSHR
Ovarian response to FSH stimulation;  276400; FSHR
Ovarioleukodystrophy;  603896; EIF2B2
Ovarioleukodystrophy;  603896; EIF2B4
Ovarioleukodystrophy;  603896; EIF2B5
Pachyonychia congenita Jackson Lawler type;  167210; KRT17
Pachyonychia congenita Jackson Lawler type;  167210; KRT6B
Pachyonychia congenita, Jadassohn-Lewandowsky type;  167200; KRT16
Pachyonychia congenita, Jadassohn-Lewandowsky type;  167200; KRT6A
Paget disease of bone;  602080; PDB4
Paget disease of bone;  602080; SQSTM1
Paget disease of bone;  602080; TNFRSF11A
Paget disease, juvenile;  239000; TNFRSF11B
Pallister–Hall syndrome;  146510; GLI3
Palmoplantar hyperkeratosis and true hermaphroditism;  610644; RSPO1
Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal;  610644; RSPO1
Palmoplantar keratoderma, nonepidermolytic;  600962; KRT16
Palmoplantar keratoderma, nonepidermolytic, focal;  613000; KRT16
Palmoplantar verrucous nevus, unilateral;  144200; KRT16
Pancreatic agenesis;  260370; IPF1
Pancreatic cancer;  260350; TP53
Pancreatic cancer;  613347; BRCA2
Pancreatic cancer/melanoma syndrome;  606719; CDKN2A
Pancreatic carcinoma, somatic;  260350; KRAS
Pancreatitis, hereditary;  167800; PRSS1
Pancreatitis, hereditary;  167800; SPINK1
Panhypopituitarism, X-linked;  312000; SOX3
Papillon–Lefèvre syndrome;  245000; CTSC
Paraganglioma and gastric stromal sarcoma;  606864; SDHB
Paraganglioma and gastric stromal sarcoma;  606864; SDHC
Paraganglioma and gastric stromal sarcoma;  606864; SDHD
Paraganglioma, familial chromaffin, 4;  115310; SDHB
Paragangliomas 2;  601650; SDHAF2
Paragangliomas, familial nonchromaffin, 1, with or without deafness;  168000; SDHD
Paragangliomas, familial nonchromaffin, 3;  605373; SDHC
Paramyotonia congenita;  168300; SCN4A
Parathyroid adenoma with cystic changes;  145001; HRPT2
Parathyroid carcinoma;  608266; HRPT2
Parietal foramina 1;  168500; MSX2
Parietal foramina 2;  609597; ALX4
Parietal foramina with cleidocranial dysplasia;  168550; MSX2
Parkes Weber syndrome;  608355; RASA1
Parkinson disease 11;  607688; GIGYF2
Parkinson disease 13;  610297; HTRA2
Parkinson disease 15, autosomal recessive;  260300; FBXO7
Parkinson disease 4;  605543; SNCA
Parkinson disease 6, early onset;  605909; PINK1
Parkinson disease 7, autosomal recessive early-onset;  606324; DJ1
Parkinson disease 9;  606693; ATP13A2
Parkinson disease, juvenile, type 2;  600116; PRKN
Parkinson disease-8;  607060; LRRK2
Parkinsonism-dystonia, infantile;  613135; SLC6A3
Paroxysmal extreme pain disorder;  167400; SCN9A
Paroxysmal nocturnal hemoglobinuria, somatic;  300818; PIGA
Paroxysmal nonkinesigenic dyskinesia;  118800; MR1
Partington syndrome;  309510; ARX
PCWH syndrome;  609136; SOX10
Peeling skin syndrome, acral type;  609796; TGM5
Pelger–Huët anomaly;  169400; LBR
Pelizaeus–Merzbacher disease;  312080; PLP1
Pendred syndrome;  274600; SLC26A4
Pentosuria;  260800; DCXR
Periodic fever, familial;  142680; TNFRSF1A
Periodontitis, juvenile;  170650; CTSC
Periventricular heterotopia with microcephaly;  608097; ARFGEF2
Peroxisomal acyl-CoA oxidase deficiency;  264470; ACOX1
Perry syndrome;  168605; DCTN1
Persistent Mullerian duct syndrome, type I;  261550; AMH
Persistent Mullerian duct syndrome, type II;  261550; AMHR2
Persistent truncus arteriosus;  217095; NKX2-6
Peters anomaly;  604229; CYP1B1
Peters anomaly;  604229; PAX6
Peters anomaly;  604229; PITX2
Peters-plus syndrome;  261540; B3GALTL; B3GTL
Peutz–Jeghers syndrome;  175200; STK11
Pfeiffer syndrome;  101600; FGFR1
Pfeiffer syndrome;  101600; FGFR2
Phenylketonuria;  261600; PAH
Pheochromocytoma;  171300; KIF1B
Pheochromocytoma;  171300; RET
Pheochromocytoma;  171300; SDHB
Pheochromocytoma;  171300; SDHD
Pheochromocytoma;  171300; VHL
Phosphoglycerate dehydrogenase deficiency;  601815; PHGDH
Phosphoglycerate kinase 1 deficiency;  300653; PGK1
Phosphoribosylpyrophosphate synthetase superactivity;  300661; PRPS1
Phosphorylase kinase deficiency of liver and muscle, autosomal recessive;  261750; PHKB
Phosphoserine aminotransferase deficiency;  610992; PSAT1
Pick disease;  172700; MAPT
Pick disease;  172700; PSEN1
Piebaldism;  172800; SNAI2
Pierson syndrome;  609049; LAMB2
Pigmented adrenocortical disease, primary, 1;  610489; PRKAR1A
Pigmented nodular adrenocortical disease, primary, 2;  610475; PDE11A
Pigmented paravenous chorioretinal atrophy;  172870; CRB1
Pilomatricoma;  132600; CTNNB1
Pitt–Hopkins-like syndrome 1;  610042; CNTNAP2
Pitt–Hopkins syndrome;  610954; TCF4
Pituitary adenoma, ACTH-secreting;  219090; AIP
Pituitary adenoma, growth hormone-secreting;  102200; AIP
Pituitary adenoma, prolactin-secreting;  600634; AIP
Pituitary hormone deficiency, combined, 1;  613038; POU1F1
Pituitary hormone deficiency, combined, 2;  262600; PROP1
Pituitary hormone deficiency, combined, 3;  221750; LHX3
Pituitary hormone deficiency, combined, 4;  262700; LHX4
Pituitary hormone deficiency, combined, 5;  182230; HESX1
Plamoplantar keratoderma, epidermolytic;  144200; KRT1
Plasminogen activator inhibitor, type I;  613329; PAI1
Platelet disorder, familial, with associated myeloid malignancy;  601399; RUNX1
Platelet glycoprotein IV deficiency;  608404; CD36
Pleuropulmonary blastoma;  601200; DICER1
Pneumothorax, primary spontaneous;  173600; FLCN
Poikiloderma with neutropenia;  604173; C16orf57
Polycystic kidney and hepatic disease;  263200; FCYT
Polycystic kidney disease 2;  613095; PKD2
Polycystic kidney disease, adult type I;  173900; PKD1
Polycystic liver disease;  174050; PRKCSH
Polycystic liver disease;  174050; SEC63
Polycystic ovary syndrome;  184700; FST
Polycythemia vera;  263300; JAK2
Polycythemia, benign familial;  263400; VHL
Polydactyly, postaxial, types A1 and B;  174200; GLI3
Polydactyly, preaxial type II;  174500; LMBR1
Polydactyly, preaxial, type IV;  174700; GLI3
Polyhydramnios, megalencephaly, and symptomatic epilepsy;  611087; STRADA
Polymicrogyria with optic nerve hypoplasia;  613180; TUBA8
Polymicrogyria, asymmetric;  610031; TUBB2B
Polymicrogyria, bilateral frontoparietal;  606854; GPR56
Polyposis syndrome, hereditary mixed, 2;  610069; BMPR1A
Polyposis, juvenile intestinal;  174900; BMPR1A
Polyposis, juvenile intestinal;  174900; MADH4
Pontocerebellar hypoplasia type 1;  607596; VRK1
Pontocerebellar hypoplasia type 2A;  277470; TSEN54
Pontocerebellar hypoplasia type 2B;  612389; TSEN2
Pontocerebellar hypoplasia type 2C;  612390; TSEN34
Pontocerebellar hypoplasia type 4;  225753; TSEN54
Pontocerebellar hypoplasia, type 6;  611523; RARS2
Popliteal pterygium syndrome;  119500; IRF6
POR deficiency;  201750; POR
Porencephaly;  175780; COL4A1
Porokeratosis, disseminated superficial actinic, 1;  175900; SART3
Porphyria cutanea tarda;  176100; UROD
Porphyria variegata;  176200; PPOX
Porphyria, acute hepatic;  612740; ALAD
Porphyria, acute intermittent;  176000; HMBS
Porphyria, acute intermittent, nonerythroid variant;  176000; HMBS
Porphyria, congenital erythropoietic;  263700; UROS
Porphyria, hepatoerythropoietic;  176100; UROD
Prader–Willi syndrome;  176270; NDN
Prader–Willi syndrome;  176270; SNRPN
Precocious puberty, central;  176400; KISS1R
Precocious puberty, male;  176410; LHCGR
Premature chromosome condensation with microcephaly and mental retardation;  606858; MCPH1
Premature ovarian failure 2B;  300604; FLJ22792
Premature ovarian failure 3;  608996; FOXL2
Premature ovarian failure 4;  300510; BMP15
Premature ovarian failure 5;  611548; NOBOX
Premature ovarian failure 6;  612310; FIGLA
Premature ovarian failure 7;  612964; NR5A1
Premature ovarian failure;  300511; DIAPH2
Primary lateral sclerosis, juvenile;  606353; ALS2
Prion disease with protracted course;  606688; PRNP
Progesterone resistance;  264080; PGR
Progressive external ophthalmoplegia with mitochondrial DNA deletions 3;  609283; SLC25A4
Progressive external ophthalmoplegia with mitochondrial DNA deletions 3;  609286; C10orf2
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4;  610131; POLG2
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 5;  613077; RRM2B
Progressive external ophthalmoplegia, autosomal dominant, with or without hypogonadism;  157640; POLG
Progressive external ophthalmoplegia, autosomal recessive;  258450; POLG
Progressive familial heart block, type IB;  604559; TRPM4
Proguanil poor metabolizer;  609535; CYP2C
Prolidase deficiency;  170100; PEPD
Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome;  225790; FLVCR2
Properdin deficiency, X-linked;  312060; PFC
Propionicacidemia;  606054; PCCA
Propionicacidemia;  606054; PCCB
Prostate cancer 1, 176807;  601518; RNASEL
Prostate cancer;  176807; BRCA2
Prostate cancer, hereditary;  176807; MSR1
Prostate cancer, progression and metastasis of;  603688; EPHB2
Prostate cancer, somatic;  176807; KLF6
Prostate cancer, somatic;  176807; MAD1L1
Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis;  308990; CLCN5
Protoporphyria, erythropoietic, autosomal dominant;  177000; FECH
Protoporphyria, erythropoietic, autosomal recessive;  177000; FECH
Protoporphyria, erythropoietic, X-linked dominant;  300752; ALAS2
Proud syndrome;  300004; ARX
Pseudoachondroplasia;  177170; COMP
Pseudohermaphroditism, male, with gynecomastia;  264300; HSD17B3
Pseudohyperkalemia, familial;  177720; PIEZO1
Pseudohypoaldosteronism type I, autosomal dominant;  177735; NR3C2
Pseudohypoaldosteronism type II;  145260; WNK4
Pseudohypoaldosteronism, type I;  264350; SCNN1A
Pseudohypoaldosteronism, type I;  264350; SCNN1B
Pseudohypoaldosteronism, type I;  264350; SCNN1G
Pseudohypoaldosteronism, type IIC;  145260; WNK1
Pseudohypoparathyroidism Ia;  103580; GNAS
Pseudohypoparathyroidism Ib;  603233; GNAS
Pseudohypoparathyroidism Ic;  612462; GNAS
Pseudohypoparathyroidism, type IB;  603233; GNASAS
Pseudohypoparathyroidism, type IB;  603233; STX16
Pseudovaginal perineoscrotal hypospadias;  264600; SRD5A2
Pseudoxanthoma elasticum;  264800; ABCC6
Pseudoxanthoma elasticum, forme fruste;  177850; ABCC6
Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency;  610842; GGCX
Ptosis, congenital;  178300; ZFHX4
Pulmonary alveolar microlithiasis;  265100; SLC34A2
Pulmonary alveolar proteinosis;  300770; CSF2RA
Pulmonary fibrosis, idiopathic;  178500; SFTPA2
Pulmonary hypertension, familial primary;  178600; BMPR2
Pulmonary hypertension, primary;  178600; MADH9
Pulmonary hypertension, primary, fenfluramine-associated;  178600; BMPR2
Pulmonary veno occlusive disease;  265450; BMPR2
Pycnodysostosis;  265800; CTSK
Pyogenic bacterial infections, recurrent, due to MYD88 deficiency;  612260; MYD88
Pyogenic sterile arthritis, pyoderma gangrenosum, and acne;  604416; PSTPIP1
Pyridoxamine 5'-phosphate oxidase deficiency;  610090; PNPO
Pyropoikilocytosis;  266140; SPTA1
Pyruvate carboxylase deficiency;  266150; PC
Pyruvate dehydrogenase deficiency;  312170; PDHA1
Pyruvate dehydrogenase E2 deficiency;  245348; DLAT
Pyruvate dehydrogenase phosphatase deficiency;  608782; PDP1
Pyruvate kinase deficiency;  266200; PKLR
Rabson–Mendenhall syndrome;  262190; INSR
Radioulnar synostosis with amegakaryocytic thrombocytopenia;  605432; HOXA11
Raine syndrome;  259775; FAM20C
RAPADILINO syndrome;  266280; RECQL4
Rapp–Hodgkin syndrome;  129400; TP63
Recombination rate QTL 1;  612042; RNF212
Refsum disease;  266500; PEX7
Refsum disease;  266500; PHYH
Refsum disease, infantile form;  266510; PEX26
Refsum disease, infantile form;  266510; PXMP3
Refsum disease, infantile;  266510; PEX1
Renal adysplasia;  191830; UPK3A
Renal agenesis;  191830; RET
Renal carcinoma, chromophobe, somatic;  144700; FLCN
Renal cell carcinoma;  144700; DIRC2
Renal cell carcinoma;  144700; HNF1A
Renal cell carcinoma;  144700; RNF139
Renal cell carcinoma, clear cell, somatic;  144700; OGG1
Renal cell carcinoma, papillary, 1;  605074; PRCC
Renal cell carcinoma, papillary, 1;  605074; TFE3
Renal cell carcinoma, papillary, familial and sporadic;  605074; MET
Renal cell carcinoma, somatic;  144700; VHL
Renal cysts and diabetes syndrome;  137920; HNF1B
Renal glucosuria;  233100; SLC5A2
Renal tubular acidosis with deafness;  267300; ATP6B1
Renal tubular acidosis, distal, AD;  179800; SLC4A1
Renal tubular acidosis, distal, AR;  611590; SLC4A1
Renal tubular acidosis, distal, autosomal recessive;  602722; ATP6V0A4
Renal tubular acidosis, proximal, with ocular abnormalities;  604278; SLC4A4
Renal tubular dysgenesis;  267430; ACE
Renal tubular dysgenesis;  267430; AGT
Renal tubular dysgenesis;  267430; AGTR1
Renal tubular dysgenesis;  267430; REN
Renal-hepatic-pancreatic dysplasia;  208540; NPHP3
Renpenning syndrome;  309500; PQBP1
Restrictive dermopathy, lethal;  275210; ZMPSTE24
Reticular dysgenesis;  267500; AK2
Retinal cone dystrophy 3;  610024; PDE6H
Retinal cone dystrophy 3B;  610356; KCNV2
Retinal cone dystrophy 4;  610478; CACNA2D4
Retinal degeneration, late-onset, autosomal dominant;  605670; C1QTNF5
Retinal dystrophy, early-onset severe;  248200; ABCA4
Retinal dystrophy, early-onset severe;  613341; LRAT
Retinitis pigmentosa 33;  610359; SNRNP200
Retinitis pigmentosa 51;  613464; TTC8
Retinitis pigmentosa 54;  613428; C2orf71
Retinitis pigmentosa 55;  613575; ARL6
Retinitis pigmentosa 58;  613617; ZNF513
Retinitis pigmentosa, concentric;  613194; BEST1
Retinitis pigmentosa, digenic;  608133; PRPH2
Retinitis pigmentosa, juvenile;  613341; LRAT
Retinitis pigmentosa, juvenile, autosomal recessive;  268000; SPATA7
Retinitis pigmentosa, late-onset dominant;  268000; CRX
Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness;  300455; RPGR
Retinitis pigmentosa-1;  180100; RP1
Retinitis pigmentosa-10;  180105; IMPDH1
Retinitis pigmentosa-11;  600138; PRPF31
Retinitis pigmentosa-12, autosomal recessive;  600105; CRB1
Retinitis pigmentosa-13;  600059; PRPF8
Retinitis pigmentosa-14;  600132; TULP1
Retinitis pigmentosa-17;  600852; CA4
Retinitis pigmentosa-18;  601414; HPRP3
Retinitis pigmentosa-19;  601718; ABCA4
Retinitis pigmentosa-2;  312600; RP2
Retinitis pigmentosa-25;  602772; EYS
Retinitis pigmentosa-26;  608380; CERKL
Retinitis pigmentosa-3;  300029; RPGR
Retinitis pigmentosa-30;  607921; FSCN2
Retinitis pigmentosa-31;  609923; TOPORS
Retinitis pigmentosa-35;  610282; SEMA4A
Retinitis pigmentosa-36;  610599; PRCD
Retinitis pigmentosa-37;  611131; NR2E3
Retinitis pigmentosa-38;  268000; MERTK
Retinitis pigmentosa-39;  268000; USH2A
Retinitis pigmentosa-41;  612095; PROM1
Retinitis pigmentosa-42;  612943; KLHL7
Retinitis pigmentosa-45;  268000; CNGB1
Retinitis pigmentosa-50;  613194; BEST1
Retinitis pigmentosa-7;  608133; PRPH2
Retinitis pigmentosa-9;  180104; RP9
Retinitis punctata albescens;  136880; PRPH2
Retinitis punctata albescens;  136880; RLBP1
Retinopathy of prematurity;  133780; FZD4
Rett syndrome;  312750; MECP2
Rett syndrome, congenital variant;  613454; FOXG1B
Rett syndrome, preserved speech variant;  312750; MECP2
Revesz syndrome;  268130; TINF2
Reynolds syndrome;  613471; LBR
Rhabdoid predisposition syndrome 1;  609322; SMARCB1
Rhabdoid tumor predisposition syndrome 2;  613325; SMARCA4
Rhabdomyosarcoma 2, alveolar;  268220; PAX3
Rhabdomyosarcoma 2, alveolar;  268220; PAX7
Rhabdomyosarcoma;  268210; SLC22A1L
Rhabdomyosarcoma, alveolar;  268220; FOXO1A
Rhizomelic chondrodysplasia punctata type 1;  215100; PEX7
Rhizomelic chondrodysplasia punctata type 3;  600121; AGPS
Ribose-5-phosphate isomerase deficiency;  608611; RPIA
Rickets due to defect in vitamin D 25-hydroxylation;  600081; CYP2R1
Rickets, vitamin D-resistant, type IIA;  277440; VDR
RIDDLE syndrome;  611943; RNF168
Rieger or Axenfeld anomalies;  602482; FOXC1
Ring dermoid of cornea;  180550; PITX2
Rippling muscle disease;  606072; CAV3
Rippling muscle disease-1;  606072; RMD1
Roberts syndrome;  268300; ESCO2
Robinow syndrome, autosomal recessive;  268310; ROR2
Rolandic epilepsy, mental retardation, and speech dyspraxia;  300643; SRPX2
Rothmund–Thomson syndrome;  268400; RECQL4
Roussy–Lévy syndrome;  180800; MPZ
Roussy–Lévy syndrome;  180800; PMP22
Rubenstein-Taybi syndrome;  180849; CREBBP
Rubinstein–Taybi syndrome;  180849; EP300
Saccharopinuria;  268700; AASS
Saethre–Chotzen syndrome with eyelid anomalies;  101400; TWIST1
Saethre–Chotzen syndrome;  101400; FGFR2
Saethre–Chotzen syndrome;  101400; TWIST1
Salla disease;  604369; SLC17A5
Sandhoff disease, infantile, juvenile, and adult forms;  268800; HEXB
Sanfilippo syndrome, type A;  252900; SGSH
Sanfilippo syndrome, type B;  252920; NAGLU
Sanfilippo syndrome, type C;  252930; HGSNAT
Sarcoidosis, early-onset;  609464; NOD2
SC phocomelia syndrome;  269000; ESCO2
Scapuloperoneal myopathy, X-linked dominant;  300695; FHL1
Scapuloperoneal spinal muscular atrophy;  181405; TRPV4
Scapuloperoneal syndrome, myopathic type;  181430; MYH7
Scapuloperoneal syndrome, neurogenic, Kaeser type;  181400; DES
Schimke immunoosseous dysplasia;  242900; SMARCAL1
Schindler disease, type I;  609241; NAGA
Schindler disease, type III;  609241; NAGA
Schinzel–Giedion midface retraction syndrome;  269150; SETBP1
Schizencephaly;  269160; EMX2
Schizophrenia;  181500; DISC2
Schneckenbecken dysplasia;  269250; SLC35D1
Schöpf–Schulz–Passarge syndrome;  224750; WNT10A
Schwannomatosis;  162091; NF2
Schwartz–Jampel syndrome, type 1;  255800; HSPG2
Sclerosteosis;  269500; SOST
Sea-blue histiocyte disease;  269600; APOE
Sebastian syndrome;  605249; MYH9
Seborrhea-like dermatitis with psoriasiform elements;  610227; ZNF750
Seckel syndrome 1;  210600; ATR
SED congenita;  183900; COL2A1
Segawa syndrome, recessive;  605407; TH
Self-healing collodion baby;  242300; TGM1
SEMD, Pakistani type;  612847; PAPSS2
Senior–Loken syndrome 4;  606996; NPHP4
Senior–Loken syndrome 5;  609254; IQCB1
Senior–Loken syndrome 6;  610189; CEP290
Senior–Loken syndrome-1;  266900; NPHP1
Sensorineural deafness with mild renal dysfunction;  602522; BSND
Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis;  607459; POLG
Septo-optic dysplasia;  182230; HESX1
SERKAL syndrome;  611812; WNT4
Sertoli cell-only syndrome;  400042; ZNF148
SESAME syndrome;  612780; KCNJ10
Severe combined immunodeficiency due to ADA deficiency;  102700; ADA
Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation;  611291; NHEJ1
Severe combined immunodeficiency, Athabascan type;  602450; DCLRE1C
Severe combined immunodeficiency, B cell-negative;  601457; RAG1
Severe combined immunodeficiency, B cell-negative;  601457; RAG2
Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive;  608971; CD3D
Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive;  608971; CD3E
Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive;  608971; PTPRC
Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type;  608971; IL7R
Severe combined immunodeficiency, X-linked;  300400; IL2RG
Short QT syndrome-1;  609620; KCNH2
Short QT syndrome-2;  609621; KCNQ1
Short QT syndrome-3;  609622; KCNJ2
Short rib-polydactyly syndrome, type III;  263510; DYNC2H1
Short stature;  604271; GHSR
Short stature, idiopathic familial;  300582; SHOX
Short stature, idiopathic familial;  300582; SHOXY
Short stature, idiopathic;  604271; GHR
Shprintzen–Goldberg syndrome;  182212; FBN1
Shwachman–Bodian–Diamond syndrome;  260400; SBDS
Sialic acid storage disorder, infantile;  269920; SLC17A5
Sialidosis, type I;  256550; NEU1
Sialidosis, type II;  256550; NEU1
Sialuria;  269921; GNE
Sick sinus syndrome 1;  608567; SCN5A
Sick sinus syndrome 2;  163800; HCN4
Sickle cell anemia;  603903; HBB
Silver spastic paraplegia syndrome;  270685; BSCL2
Silver–Russell syndrome;  180860; H19
Simpson-Golabi-Behmel syndrome, type 1;  312870; GPC3
Simpson-Golabi-Behmel syndrome, type 2;  300209; OFD1
Sitosterolemia;  210250; ABCG5
Sitosterolemia;  210250; ABCG8
Sjögren–Larsson syndrome;  270200; ALDH3A2
Skeletal defects, genital hypoplasia, and mental retardation;  612447; ZBTB16
Skin fragility-woolly hair syndrome;  607655; DSP
Skin/hair/eye pigmentation 9, dark/light hair;  611742; ASIP
Slowed nerve conduction velocity, AD;  608236; ARHGEF10
Small patella syndrome;  147891; TBX4
SMED, Strudwick type;  184250; COL2A1
Smith–Lemli–Opitz syndrome;  270400; DHCR7
Smith–Magenis syndrome;  182290; RAI1
Smith–McCort dysplasia;  607326; DYM
Snowflake vitreoretinal degeneration;  193230; KCNJ13
Solitary median maxillary central incisor;  147250; SHH
Somatostatin analog, resistance to;  102200; SSTR5
Sorsby fundus dystrophy;  136900; TIMP3
Sotos syndrome;  117550; NSD1
Spastic ataxia, Charlevoix-Saguenay type;  270550; SACS
Spastic paralysis, infantile onset ascending;  607225; ALS2
Spastic paraplegia 10;  604187; KIF5A
Spastic paraplegia 15;  270700; ZFYVE26
Spastic paraplegia 31;  610250; REEP1
Spastic paraplegia 33;  610244; ZFYVE27
Spastic paraplegia 39;  612020; PNPLA6
Spastic paraplegia, 44;  613206; GJC2
Spastic paraplegia-11;  604360; SPG11
Spastic paraplegia-13;  605280; HSPD1
Spastic paraplegia-2;  312920; PLP1
Spastic paraplegia-3A;  182600; SPG3A
Spastic paraplegia-4;  182601; SPAST
Spastic paraplegia-42;  612539; SLC33A1
Spastic paraplegia-5A;  270800; CYP7B1
Spastic paraplegia-6;  600363; NIPA1
Spastic paraplegia-7;  607259; PGN
Spastic paraplegia-8;  603563; KIAA0196
Specific granule deficiency;  245480; CEBPE
Speech-language disorder-1;  602081; FOXP2
Spherocytosis, hereditary, type 5;  612690; EPB42
Spherocytosis, type 1;  182900; ANK1
Spherocytosis, type 3;  270970; SPTA1
Spherocytosis, type 4;  612653; SLC4A1
Spinal and bulbar muscular atrophy of Kennedy;  313200; AR
Spinal muscular atrophy, distal, autosomal recessive, 4;  611067; PLEKHG5
Spinal muscular atrophy, distal, X-linked 3;  300489; ATP7A
Spinal muscular atrophy, late-onset, Finkel type;  182980; VAPB
Spinal muscular atrophy, X-linked 2, infantile;  301830; UBE1
Spinal muscular atrophy-1;  253300; SMN1
Spinal muscular atrophy-2;  253550; SMN1
Spinal muscular atrophy-3;  253400; SMN1
Spinal muscular atrophy-4;  271150; SMN1
Spinocerebellar ataxia 12;  604326; PPP2R2B
Spinocerebellar ataxia 14;  605361; PRKCG
Spinocerebellar ataxia 15;  606658; ITPR1
Spinocerebellar ataxia 17;  607136; TBP
Spinocerebellar ataxia 28;  610246; AFG3L2
Spinocerebellar ataxia 31;  117210; BEAN
Spinocerebellar ataxia 8;  608768; ATXN8OS
Spinocerebellar ataxia 8;  608768; ATXN8
Spinocerebellar ataxia with epilepsy;  607459; POLG
Spinocerebellar ataxia, autosomal recessive 5;  606937; ZNF592
Spinocerebellar ataxia, autosomal recessive 8;  610743; SYNE1
Spinocerebellar ataxia, autosomal recessive 9;  612016; CABC1
Spinocerebellar ataxia, autosomal recessive with axonal neuropathy;  607250; TDP1
Spinocerebellar ataxia, infantile-onset;  271245; C10orf2
Spinocerebellar ataxia-1;  164400; ATXN1
Spinocerebellar ataxia-10;  603516; ATXN10
Spinocerebellar ataxia-11;  604432; TTBK2
Spinocerebellar ataxia-13;  605259; KCNC3
Spinocerebellar ataxia-2;  183090; ATXN2
Spinocerebellar ataxia-27;  609307; FGF14
Spinocerebellar ataxia-5;  600224; SPTBN2
Spinocerebellar ataxia-6;  183086; CACNA1A
Spinocerebellar ataxia-7;  164500; ATXN7
Split-hand/foot malformation 6;  225300; WNT10B
Split-hand/foot malformation, type 4;  605289; TP63
Spondylocarpotarsal synostosis syndrome;  272460; FLNB
Spondylocheirodysplasia, Ehlers-Danlos syndrome-like;  612350; SLC39A13
Spondylocostal dysostosis, autosomal recessive 2;  608681; MESP2
Spondylocostal dysostosis, autosomal recessive 3;  609813; LFNG
Spondylocostal dysostosis, autosomal recessive, 1;  277300; DLL3
Spondylocostal dystostosis 4, autosomal dominant;  122600; GDF6
Spondyloepimetaphyseal dysplasia;  608728; MATN3
Spondyloepimetaphyseal dysplasia, aggrecan type;  612813; ACAN
Spondyloepimetaphyseal dysplasia, Missouri type;  602111; MMP13
Spondyloepiphyseal dysplasia tarda with progressive arthropathy;  208230; WISP3
Spondyloepiphyseal dysplasia tarda;  313400; TRAPPC2
Spondyloepiphyseal dysplasia with congenital joint dislocations;  143095; CHST3
Spondyloepiphyseal dysplasia, Kimberley type;  608361; ACAN
Spondylo-megaepiphyseal-metaphyseal dysplasia;  613330; NKX3-2
Spondylometaepiphyseal dysplasia, short limb-hand type;  271665; DDR2
Spondylometaphyseal dysplasia, Kozlowski type;  184252; TRPV4
Spondyloperipheral dysplasia;  271700; COL2A1
Squamous cell carcinoma, head and neck;  275355; ING1
Squamous cell carcinoma, head and neck;  275355; TNFRSF10B
Stapes ankylosis with broad thumb and toes;  184460; NOG
STAR syndrome;  300707; FAM58A
Stargardt disease 3;  600110; ELOVL4
Stargardt disease 4;  603786; PROM1
Stargardt disease-1;  248200; ABCA4
Startle disease/hyperekplexia, autosomal dominant;  149400; GLRA1
Steatocystoma multiplex;  184500; KRT17
Stickler syndrome, type I;  108300; COL2A1
Stickler syndrome, type II;  604841; COL11A1
Stickler syndrome, type III;  184840; COL11A2
Stiff skin syndrome;  184900; FBN1
Stocco dos Santos X-linked mental retardation syndrome;  300434; SHROOM4
Stomach cancer;  137215; KRAS
Stomatocytosis I;  185000; EPB72
Striatal degeneration, autosomal dominant;  609161; PDE8B
Striatonigral degeneration, infantile;  271930; NUP62
Stuve–Wiedemann syndrome/Schwartz–Jampel type 2 syndrome;  601559; LIFR
Subcortical laminal heteropia, X-linked;  300067; DCX
Succinic semialdehyde dehydrogenase deficiency;  271980; ALDH5A1
Succinyl-CoA:3-oxoacid CoA transferase deficiency;  245050; OXCT1
Sucrase-isomaltase deficiency, congenital;  222900; SI
Sudden infant death with dysgenesis of the testes syndrome;  608800; TSPYL1
Sulfite oxidase deficiency;  272300; SUOX
Supranuclear palsy, progressive atypical;  260540; MAPT
Supranuclear palsy, progressive;  601104; MAPT
Supravalvar aortic stenosis;  185500; ELN
Surfactant metabolism dysfunction, pulmonary, 1;  265120; SFTPB
Surfactant metabolism dysfunction, pulmonary, 2;  610913; SFTPC
Surfactant metabolism dysfunction, pulmonary, 3;  610921; ABCA3
Sveinsson choreoretinal atrophy;  108985; TEAD1
Symphalangism, proximal;  185800; GDF5
Symphalangism, proximal;  185800; NOG
Syndactyly, type III;  186100; GJA1
Syndactyly, type IV;  186200; LMBR1
Syndactyly, type V;  186300; HOXD13
Synostoses syndrome, multiple, 1;  186500; NOG
Synpolydactyly with foot anomalies;  186000; HOXD13
Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses;  608180; FBLN1
Synpolydactyly, type II;  186000; HOXD13
Tangier disease;  205400; ABCA1
TARP syndrome;  311900; RBM10
Tarsal-carpal coalition syndrome;  186570; NOG
Tay–Sachs disease;  272800; HEXA
T-cell immunodeficiency, congenital alopecia, and nail dystrophy;  601705; FOXN1
Testicular microlithiasis;  610441; SLC34A2
Testicular tumor, sporadic;  273300; STK11
Tetra-amelia, autosomal recessive;  273395; WNT3
Tetralogy of Fallot;  187500; GDF1
Tetralogy of Fallot;  187500; JAG1
Tetralogy of Fallot;  187500; ZFPM2
Tetrology of Fallot;  187500; NKX2E
Thalassemia, alpha-;  604131; HBA2
Thalassemia, Hispanic gamma-delta-beta;  604131; LCRB
Thalassemia-beta, dominant inclusion-body;  603902; HBB
Thalassemias, alpha-;  604131; HBA1
Thalassemias, beta-;  604131; HBB
Thanatophoric dysplasia, type I;  187600; FGFR3
Thiamine-responsive megaloblastic anemia syndrome;  249270; SLC19A2
Three M syndrome 2;  612921; OBSL1
Thrombocythemia, essential;  187950; JAK2
Thrombocythemia, essential;  187950; MPL
Thrombocythemia, essential;  187950; THPO
Thrombocytopenia 4;  612004; CYCS
Thrombocytopenia with beta-thalassemia, X-linked;  314050; GATA1
Thrombocytopenia, congenital amegakaryocytic;  604498; MPL
Thrombocytopenia, X-linked;  313900; WAS
Thrombocytopenia, X-linked, intermittent;  313900; WAS
Thrombocytopenia-2;  188000; FLJ14813
Thrombocytopenic purpura, autoimmune;  188030; FCGR2C
Thrombophilia due to elevated HRG;  613116; HRG
Thrombophilia due to heparin cofactor II deficiency;  612356; HCF2
Thrombophilia due to HRG deficiency;  613116; HRG
Thrombophilia due to protein C deficiency, autosomal dominant;  176860; PROC
Thrombophilia due to protein C deficiency, autosomal recessive;  612304; PROC
Thrombophilia due to protein S deficiency;  612336; PROS1
Thrombophilia, familial, due to decreased release of PLAT;  612348; PLAT
Thrombophilia, X-linked, due to factor IX defect;  300807; F9
Thrombosis, hyperhomocysteinemic;  236200; CBS
Thrombotic thrombocytopenic purpura, familial;  274150; ADAMTS13
Thryoid dyshormonogenesis 6;  607200; DUOX2
Thyroid carcinoma, follicular;  188470; MINPP1
Thyroid carcinoma, follicular;  188470; NRAS
Thyroid carcinoma, papillary;  188550; GOLGA5
Thyroid carcinoma, papillary;  188550; NCOA4
Thyroid carcinoma, papillary;  188550; PCM1
Thyroid carcinoma, papillary;  188550; PRKAR1A
Thyroid carcinoma, papillary;  188550; TRIM24
Thyroid carcinoma, papillary;  188550; TRIM33
Thyroid dyshormonogenesis 1;  274400; SLC5A5
Thyroid dyshormonogenesis 2A;  274500; TPO
Thyroid dyshormonogenesis 3;  274700; TG
Thyroid dyshormonogenesis 4;  274800; IYD
Thyroid dyshormonogenesis 5;  274900; DUOXA2
Thyroid hormone metabolism, abnormal;  609698; SECISBP2
Thyroid hormone resistance;  188570; THRB
Thyroid hormone resistance, autosomal recessive;  274300; THRB
Thyroid hormone resistance, selective pituitary;  145650; THRB
Thyroid papillary carcinoma;  188550; CCDC6
Tibial muscular dystrophy, tardive;  600334; TTN
Tietz albinism-deafness syndrome;  103500; MITF
Timothy syndrome;  601005; CACNA1C
Tn syndrome;  300622; C1GALT1C1
Toenail dystrophy, isolated;  607523; COL7A1
Tooth agenesis, selective, 1, with or without orofacial cleft;  106600; MSX1
Tooth agenesis, selective, 3;  604625; PAX9
Tooth agenesis, selective, 6;  613097; LTBP3
Tooth agenesis, selective, X-linked 1;  313500; ED1
Torg–Winchester syndrome;  259600; MMP2
Tourette syndrome;  137580; SLITRK1
Townes–Brocks branchiootorenal-like syndrome;  107480; SALL1
Townes–Brocks syndrome;  107480; SALL1
Transaldolase deficiency;  606003; TALDO1
Transcobalamin II deficiency;  275350; TCN2
Transient bullous of the newborn;  131705; COL7A1
Transposition of the great arteries, dextro-looped 1;  608808; MED13L
Treacher Collins mandibulofacial dysostosis;  154500; TCOF1
Trehalase deficiency;  612119; TREH
Trichodentoosseous syndrome;  190320; DLX3
Trichoepithelioma, multiple familial, 1;  601606; CYLD1
Trichorhinophalangeal syndrome, type I;  190350; TRPS1
Trichorhinophalangeal syndrome, type III;  190351; TRPS1
Trichothiodystrophy;  601675; ERCC2
Trichothiodystrophy;  601675; ERCC3
Trichothiodystrophy, complementation group A;  601675; GTF2H5
Trichothiodystrophy, nonphotosensitive 1;  234050; C7orf11
Trichotillomania;  613229; SLITRK1
Trifunctional protein deficiency;  609015; HADHA
Trifunctional protein deficiency;  609015; HADHB
Trigonocephaly;  190440; FGFR1
Trimethylaminuria;  602079; FMO3
Triphalangeal thumb, type I;  174500; LMBR1
Triphalangeal thumb-polysyndactyly syndrome;  174500; LMBR1
Trismus-pseudocamptodactyly syndrome;  158300; MYH8
Tropical calcific pancreatitis;  608189; SPINK1
Troyer syndrome;  275900; SPG20
Tuberous sclerosis-1;  191100; TSC1
Tuberous sclerosis-2;  191100; TSC2
Tumoral calcinosis, familial, normophosphatemic;  610455; SAMD9
Tumoral calcinosis, hyperphosphatemic;  211900; KL
Tumoral calcinosis, hyperphosphatemic, familial;  211900; FGF23
Tumoral calcinosis, hyperphosphatemic, familial;  211900; GALNT3
Tyrosine kinase 2 deficiency;  611521; TYK2
Tyrosinemia type II;  277660; TAT
Tyrosinemia type III;  276710; HPD
Ullrich congenital muscular dystrophy;  254090; COL6A1
Ullrich congenital muscular dystrophy;  254090; COL6A2
Ullrich congenital muscular dystrophy;  254090; COL6A3
Ulna and fibula, absence of, with severe limb deficiency;  276820; WNT7A
Ulnar–mammary syndrome;  181450; TBX3
Urocanase deficiency;  276880; UROC1
Urofacial syndrome;  236730; HPSE2
Usher syndrome, type 1B;  276900; MYO7A
Usher syndrome, type 1C;  276904; USH1C
Usher syndrome, type 1D;  601067; CDH23
Usher syndrome, type 1D/F digenic;  601067; CDH23
Usher syndrome, type 1D/F digenic;  601067; PCDH15
Usher syndrome, type 1F;  602083; PCDH15
Usher syndrome, type 1G;  606943; SANS
Usher syndrome, type 2A;  276901; USH2A
Usher syndrome, type 3;  276902; CLRN1
Usher syndrome, type IIC;  605472; GPR98
Usher syndrome, type IID;  611383; WHRN
UV-sensitive syndrome;  600630; ERCC6
VACTERL association;  192350; HOXD13
Van Buchem disease;  239100; SOST
van Buchem disease, type 2;  607636; LRP5
van der Woude syndrome;  119300; IRF6
Vasculopathy, retinal, with cerebral leukodystrophy;  192315; TREX1
VATER association with macrocephaly and ventriculomegaly;  276950; PTEN
Velocardiofacial syndrome;  192430; TBX1
Venous malformations, multiple cutaneous and mucosal;  600195; TEK
Ventricular fibrillation, familial, 1;  603829; SCN5A
Ventricular fibrillation, paroxysmal familial, 2;  612956; DPP6
Ventricular tachycardia, catecholaminergic polymorphic, 1;  604772; RYR2
Ventricular tachycardia, catecholaminergic polymorphic, 2;  611938; CASQ2
Ventricular tachycardia, idiopathic;  192605; GNAI2
Vertical talus, congenital;  192950; HOXD10
Vesicoureteral reflux 2;  610878; ROBO2
VEXAS;  301054; UBA1
Vitamin D-dependent rickets, type I;  264700; CYP27B1
Vitamin K-dependent clotting factors, combined deficiency of, 2;  607473; VKORC1
Vitamin K-dependent coagulation defect;  277450; GGCX
Vitelliform macular dystrophy, adult-onset;  608161; BEST1
Vitreoretinochoroidopathy;  193220; BEST1
VLCAD deficiency;  201475; ACADVL
Vohwinkel syndrome with ichthyosis;  604117; LOR
Vohwinkel syndrome;  124500; GJB2
von Hippel–Lindau disease, modification of;  193300; CCND1
von Hippel–Lindau syndrome;  193300; VHL
von Willebrand disease, autosomal dominant;  193400; VWF
von Willebrand disease, autosomal recessive;  277480; VWF
von Willebrand disease, platelet-type;  177820; GP1BA
Waardenburg syndrome type 1;  193500; PAX3
Waardenburg syndrome type 2D;  608890; SNAI2
Waardenburg syndrome type 2E, with or without neurologic involvement;  611584; SOX10
Waardenburg syndrome type 3;  148820; PAX3
Waardenburg syndrome type 4A;  277580; EDNRB
Waardenburg syndrome type 4B;  613265; EDN3
Waardenburg syndrome type 4C;  613266; SOX10
Waardenburg syndrome type IIA;  193510; MITF
Waardenburg syndrome/albinism, digenic;  103470; TYR
Waardenburg syndrome/ocular albinism, digenic;  103470; MITF
Wagner syndrome 1;  143200; VCAN
Warburg micro syndrome 1;  600118; RAB3GAP1
Warfarin resistance;  122700; VKORC1
Warfarin sensitivity;  122700; CYP2C9
Warsaw breakage syndrome;  613398; DDX11
Watson syndrome;  193520; NF1
Weaver syndrome;  277590; NSD1
Weill–Marchesani syndrome, dominant;  608328; FBN1
Weill–Marchesani syndrome, recessive;  277600; ADAMTS10
Weill–Marchesani-like syndrome;  613195; ADAMTS17
Weissenbacher–Zweymüller syndrome;  277610; COL11A2
Werner syndrome;  277700; RECQL2
Weyers acrodental dysostosis;  193530; EVC
WHIM syndrome;  193670; CXCR4
White sponge nevus;  193900; KRT13
White sponge nevus;  193900; KRT4
Wilms' tumor 2;  194071; H19
Wilms' tumor;  194070; BRCA2
Wilms' tumor, somatic;  194070; GPC3
Wilms' tumor, type 1;  194070; WT1
Wilson's disease;  277900; ATP7B
Wiskott–Aldrich syndrome;  301000; WAS
Witkop syndrome;  189500; MSX1
Wolcott–Rallison syndrome;  226980; EIF2AK3
Wolff–Parkinson–White syndrome;  194200; PRKAG2
Wolfram syndrome 2;  604928; CISD2
Wolfram syndrome;  222300; WFS1
Wolfram-like syndrome, autosomal dominant;  222300; WFS1
Wolman disease;  278000; LIPA
Woodhouse–Sakati syndrome;  241080; C2orf37
Woolly hair, autosomal dominant;  194300; KRT74
Woolly hair, autosomal recessive 1;  278150; P2RY5
Woolly hair, autosomal recessive 2 with or without hypotrichosis;  604379; LIPH
Wrinkly skin syndrome;  278250; ATP6V0A2
Xanthinuria, type I;  278300; XDH
Xeroderma pigmentosum group A;  278700; XPA
Xeroderma pigmentosum group B;  610651; ERCC3
Xeroderma pigmentosum group C;  278720; XPC
Xeroderma pigmentosum group D;  278730; ERCC2
Xeroderma pigmentosum group E, DDB-negative subtype;  278740; DDB2
Xeroderma pigmentosum group F;  278760; ERCC4
Xeroderma pigmentosum group G;  278780; ERCC5
Xeroderma pigmentosum, variant type;  278750; POLH
XFE progeroid syndrome;  610965; ERCC4
X-inactivation, familial skewed;  300087; XIC
Zellweger syndrome;  214100; PEX10
Zellweger syndrome;  214100; PEX13
Zellweger syndrome;  214100; PEX14
Zellweger syndrome;  214100; PEX26
Zellweger syndrome;  214100; PEX5
Zellweger syndrome;  214100; PXF
Zellweger syndrome, complementation group G;  214100; PEX3
Zellweger syndrome-1;  214100; PEX1

External links
https://www.ncbi.nlm.nih.gov/Omim/omimfaq.html#download